

1 **Casein : Allergenicity and molecular Properties**

2 *Linda Monaci, Rosa Pilolli, Laura Quintieri, Leonardo Caputo, Anna Luparelli, Elisabetta De Angelis*

3 Institute of Sciences of Food Production, National Research Council of Italy (CNR-ISPA), 70126 Bari, Italy

4

5 **Abstract**

6 Caseins represent about 80% of total protein in cow's milk. Individual caseins, α_1 , α_2 , β and κ -
7 casein, are characterized by specific structure and function. Besides their role in cheese-making,
8 casein subunits exhibit molecular properties and structure which confer them technological and
9 functional properties exploited in food and pharmaceutical industries for a long time. Nutritional
10 value and beneficial effects due the release of bioactive peptides are also widely reported. Despite
11 their valuable properties, caseins are able to trigger even severe immuno reactions in sensitive
12 individuals thus representing one of the most important allergenic source in the food allergens
13 landscape. Thanks to the exploitation of high throughput technologies combined with advanced
14 bioinformatic tools, the forefront research is directed to identify and characterize new epitopes
15 capable of inducing an onset of allergic reaction in predisposed consumers. On the other hand,
16 several efforts are underway to develop innovative solutions to reduce caseins allergy by preserving
17 nutritional quality of proteins. The paper aims to give a broad overview on the main proteins
18 constituting cow's milk, the related molecular properties as well as to provide some knowout about
19 their functioning properties in food processing. The focus is then moved forward to allergenic
20 properties of caseins and capability of milk proteins to trigger cow's milk allergy (CMA) in sensitive
21 consumers. Processing strategies to mitigate casein allergenicity and CMA prevention, management
22 and therapeutic approaches are also presented.

23

24

25 **Keywords:** caseins, molecular properties, functioning properties, food allergens, cow's milk allergy,
26 IgE, innovative strategies, allergenicity reduction.

27

28

29

30 1. Introduction

31 Milk proteins represent an important source of nutritional compounds due to their high biological
32 value and richness in essential aminoacids. Through acidification at pH 4.6 or ultracentrifugation,
33 these proteins can be divided in two main fractions: caseins and whey proteins, which proportions
34 in the total milk vary among the species. For instance, in human, cow, goat, camel and mare milk,
35 casein represents the most dominant fraction, with percentages ranging from 40% and 80%. Cow
36 milk shows the highest content of casein (80%), followed by goat (64.52%), mare (55%), camel (52%)
37 and human (40%). Cow milk represents the most widespread source of dairy products worldwide
38 accounting for around 82.4% of the world's fresh milk (Villa et al., 2018). As other species, casein
39 fraction from cow milk is composed by α -S1-casein, α -S2-casein, β -casein and κ -casein representing
40 40%, 12.5%, 35% and 12.5% of the whole caseins, respectively (Huppertz, 2013; Huppertz et al.,
41 2018). Different proportions of α -S1-, α -S2-, β - and κ -casein were found in other milk species (Zhao
42 et al., 2023).

43 Structure and molecular properties of casein subunits are responsible for their technological and
44 functional properties. For example, κ -casein genetic variants show different effects on
45 cheesemaking (Schaar et al., 1985) whereas the structure of individual molecules can affect flavor
46 binding, color, and digestibility (Foegeding, 2015). Aminoacid sequences are also responsible for
47 biological effects due to the release of bioactive peptides (Silva and Malcata, 2005). Caseins have
48 open and flexible conformations and contain hydrophilic and hydrophobic segments. The high
49 hydrophobicity promotes the formation of micellar structure (size from 50 to 300 nm), all four types
50 of caseins (94% on dry weight basis) and amorphous calcium phosphate, magnesium and citrate (6%
51 d.w.b.) (Ranadheera et al., 2016). Other than the micellar form, sodium or calcium salts of casein
52 (namely caseinates) are widely used ingredients in the food industry. Caseins are Generally
53 Regarded as Safe (GRAS status) and therefore are also used as a protein ingredient in various food
54 products to enhance their physical, functional (foaming, thickening, emulsification, texture) and
55 nutritional properties. Caseins possess ions and small molecules binding capacity, stabilizing and
56 emulsification activities, and gelation and water binding capacity under defined conditions
57 (Ranadheera et al., 2016); these physical properties and behaviour, make them as good candidates
58 to develop delivery systems in food and pharmaceutical industries (Sadiq et al., 2021).

59 Despite their valuable properties, caseins are able to trigger even severe immuno reactions in
60 sensitive individuals thus representing one of the most important allergenic source in the food
61 allergens landscape.

62 Several investigations demonstrated that the allergenicity of cow milk is higher than what found for
63 goat, camel and mare, even if no report has clearly determined the reasons (Zhao et al., 2023). Cow
64 caseins proteins are well known for their allergenic potential and according to the International
65 Union of Immunological Societies (WHO/IUIS) they are designed as Bos d 9 (α -S1 -), Bos d 10 (α -S2),
66 Bos d 11 (β -) and Bos d 12 (κ -), while the general code Bos d 8 is used for identifying the whole casein
67 fraction. Likewise, to functioning and functional properties, the composition and sequence of amino
68 acids determine the higher structure of proteins, which, in turn, entails the biological function of
69 proteins, including allergenicity. Although conflicting data exist concerning, milk processing
70 techniques can alter the milk fat and protein's molecular structure and serve them as allergens to
71 the immune system of allergic individuals. For instance, homogenization might increase the

72 allergenicity of the milk due to disintegration of casein micelles and milk fat globules (Poulsen et al.,
73 1987; Geiselhart et al., 2021).

74 Cow's milk allergy (CMA) is one of the most common food allergies in early life with an estimated
75 prevalence in developed countries ranging from 0.5% to 3% at age 1 year (Flom and Sicherer, 2019).
76 Allergic responses by both whey proteins and caseins in adults are rare but severe (Lam et al., 2008).
77 Multiple symptoms were produced by milk ingestion; vomiting, diarrhea, abdominal pain, asthma,
78 rhinitis, and atopic dermatitis were frequently presenting and challenge symptoms. Some patients
79 had central nervous system symptoms, urticaria, or anaphylactic reactions.

80 The allergy is typically treated by eliminating cow's milk proteins from the diet of allergic
81 individuals. Formula alternatives include hydrolyzed cow's milk formula, rice-based formula, soy-
82 based formula, and amino acid-based formula, which are all nutritionally adequate alternatives to
83 cow's milk formula (Kipfer and Goldman, 2021). However infants with CMA can also react to
84 alternative formula (Agostoni, et al. 2006). Despite the relevance of the quality of diet for infants
85 on an elimination diet, evidence of dietary nutrient deficiencies, growth deficits, and low food intake
86 are reported in patients subjected to cow's milk-free diet (Meyer, 2018; Vieira et al., 2010).
87 Therefore, milk processing strategies to inactivate allergic proteins by preserving nutritional value
88 of milk are a current challenge (Jaiswal and Worku, 2022).

89 In this context this paper details main proteins in cow milk and related molecular properties at the
90 basis of functioning properties in food processing; caseins are then deeply discussed for their
91 allergenicity in CMA. Milk processing strategies to mitigate casein allergenicity and CMA prevention,
92 management and therapeutic approaches are also presented.

93

94 **2. Main molecular properties of caseins**

95 Casein (CN) subunits are classified into 4 types: α_{s1} (40% of the total casein in bovine milk), α_{s2} (10%),
96 β (35%), and κ (15%). Molecular weight ranges from 20 to 30 kDa depending on the subunit
97 (Huppertz, 2013; Huppertz et al., 2018).

98 α_{s1} -CN contains 199 amino acids and has a molecular mass of *ca.* 23.0 kDa prior to phosphorylation,
99 which increases to \sim 23.6 kDa as a result of the phosphorylation of 8 Ser residues. Based on its
100 primary sequence, expected isoelectric point (pI) is 4.9, but this decreases by *ca.* 0.5 pH units on
101 phosphorylation of the 8 Ser residues. α_{s1} -CN is a moderately hydrophobic protein. Estimated
102 percentage of α -helix and β -sheets in α_{s1} -casein ranged from 5 to 20% and 17 to 40% (Huppertz,
103 2013; Huppertz et al., 2018).

104 α_{s2} -CN contains 207 amino acids resulting in a molar mass of *ca.* 24.3 kDa for the non-
105 phosphorylated protein and 25.2 kDa for the variant containing 11 phosphorylated Ser residues.
106 Non-phosphorylated protein has a pI of 8.3 but the phosphorylation reduces the pI to 4.9. Protein
107 can be divided into five distinct regions of high charge and low hydrophobicity (residues 1–41 and
108 42–80), a hydrophobic region with a slight positive charge (residues 81–125), a phospho-peptide
109 analog (residues 126–170) with high negative charge, and a region with high hydrophobicity and
110 strong positive charge (residues 171–207). Several studies report variable percentages of α -helix (up
111 to 54%), β -sheet (approximately 15%) of the secondary structure (Huppertz, 2013; Huppertz et al.,
112 2018). The presence of two Cys residues favour the formation of intra- or intermolecular disulphide
113 bonds with other α_{s2} -casein molecules.

114 β -CN sequence consists of 209-amino acids corresponding to molecular mass of 23.6 kDa for the
115 non-phosphorylated form and 24.0 kDa following phosphorylation of 5 Ser residues; consequently,
116 pI is estimated at 5.1 and 4.7 for non-phosphorylated and phosphorylated β -CN, respectively.
117 (Huppertz, 2013; Huppertz et al., 2018). β -CN is strongly amphipathic; the *N*-terminus region
118 (residues 1–40) contain only 2 Pro residues and have low hydrophobicity, the middle section
119 (residues 41–135) has moderate hydrophobicity, whereas the C-terminal section, (residues 136–
120 209) contains many of the apolar residues and is characterized by high hydrophobicity. The presence
121 of 7%–25% α -helix structure and 15%–33% β -sheet were reported.

122 κ -CN is the smallest of the caseins with 169-amino, a theoretical molecular weight of 18.98 Da and
123 a theoretical pI of 5.93. Likewise to other caseins, variable degrees of phosphorylation have also
124 been found for κ -CN (Huppertz, 2013). Both hydrophobicity and charge are distributed unevenly
125 throughout the protein: segment 1–20 shows predominantly hydrophilic behaviour, whereas
126 segment 21–110 contains some strongly hydrophobic patches; segment 110–120 is strongly
127 hydrophilic, whereas the segment 121–169 shows some hydrophilic and hydrophobic areas
128 (Huppertz, 2013). As concern the secondary structure, several studies report that κ -CN may contain
129 10–20% α -helix, 20–30% β -structure and 15–25% turns (Huppertz, 2013).

130

131 **3. Functioning properties and applications**

132 The diverse protein caseins have been extensively studied due to their importance in milk, as food
133 additives and as emulsifiers and stabilizers for glue, paint, and other materials (Audic et al., 2003;
134 O'Donoghue and Murphy, 2023). Although the exact structure and nature of casein micelles are still
135 under debate, these proteins lack well-defined secondary and tertiary structure due to large amount
136 of propyl residues (Holt and Sawyer, 1993). This aspect, apparently in contrast with the known
137 relationship between structure and function of a protein, is actually very crucial for casein functional
138 properties basically due to their primary amino acid sequence.

139 Thus, caseins are considered flexible, unfolded or random-coil peptides capable of creating several
140 intermolecular interactions (Audic et al., 2003; Holt et al., 2013). Depending on the specific product,
141 caseins assume different meso or macro-structures with different functional properties that impact
142 both with perception and with their digestibility, accessibility and/or allergenicity. This concept
143 would also explain the versatility of milk caseins both in dairy products and non-food settings
144 (Foegeding and Davis, 2011; Foegeding, 2015).

145 Caseins α_{s1} -CN, α_{s2} -CN and β -CN are calcium-binding phosphoproteins as they are involved in
146 trapping of calcium phosphate up to form calcium phosphate nanoclusters. Moreover, the same
147 proteins complexing with calcium phosphate become tighter than globular proteins (Holt et al.,
148 1998). Thus, α_{s1} -CN, α_{s2} -CN and β -CN are sensitive to the Ca^{2+} ion and precipitate at the
149 concentration present in milk (De Kruif and Holt, 2003). Conversely, κ -CN is insensitive to Ca^{2+} and
150 if present in sufficient quantity it stabilizes the other caseins by preventing their precipitation (De
151 Kruif and Holt, 2003).

152 The calcium-sensitive caseins are located within the micellar structure, while κ -CN is located outside
153 with hydrophilic amino acid and glycosylated residues that protruding outwards from the micellar
154 structure as flexible filaments surrounded by the aqueous medium (Walstra model; Walstra and
155 Jenness, 1984). The submicelle structures, held together by phosphoserines complexing calcium

156 phosphate (CaP), are covered by κ -CN hydrophilic shell allowing the casein micelles to remain in
157 solution, although dependent on the pH-sensitive balance between soluble Ca^{2+} and that in
158 micelles (Huppertz et al., 2013). Thus, unlike its protein constituents, casein micelle is an ordered
159 structure providing fluidity to casein molecules and solubilize phosphate and calcium and
160 preventing calcium stones in the mammary gland in addition to providing nutritional compounds
161 (Doherty et al., 2003; Holt et al., 2013).

162 Casein proteins play an important nutritional role because of their high phosphate content due to
163 which they bind significant quantities of calcium and also are rich in lysine which is an essential
164 amino acid in humans (Fox et al., 2015).

165 Caseins are also able to form oligomers and polymers after treatment of oxidases (laccases,
166 peroxidase, tyrosinase) in the absence or presence of redox mediators (i.e. ferulic acid or
167 chlorogenic acid; Loi et al., 2020; Selinheimo et al., 2008; Li et al., 2020). Mattinen et al.
168 (2005) reported the production of homopolymers of tyrosine-containing peptides or tyrosine alone
169 with only trace amounts of the mediator cross-linked to the substrate; they also proved that a
170 reactive mediator radical was produced preferentially, and that cross-linking of the substrates
171 occurred by formation of isodityrosine bonds (C–O–C) and to a lesser extent by dityrosine bonds (C–
172 C). The formation of crosslinking also affected digestibility, functional and allergenic properties of
173 caseins (Stanic et al., 2010; Loi et al., 2018).

174 A function has been demonstrated for each of the caseins. α_{s1} -CN plays an important role in the
175 ability of milk to transport calcium phosphate. It has also been found that one of its peptide (f(64-
176 68)) has radical scavenging activity (Creamer et al., 1981; Kitts and Weiler, 2003). Also, β -CN plays
177 an important role in determining the surface property of casein micelle. Some β -CN peptides f(1-
178 18), f(105-117), f(191-193) act as a macrophage activator and immunomodulators, increasing the
179 phagocytic activity and peroxide release; another β -CN peptide (f(98-105)) also possesses
180 antioxidant activity (Migliore-Samour and Jolles, 1988; Azuma et al., 1989; Rival et al., 2001).

181 α_{s1} - and β -casein are also responsible for the stabilization of micelle by preventing aggregation of
182 α_{s2} - and κ -casein, respectively (chaperonic activity). This activity has also been demonstrated
183 towards other proteins like bovine serum albumin, whey proteins, β -lactoglobulin, carbonic
184 anhydrase and alcohol dehydrogenase preventing their stress-induced aggregation and forming
185 soluble, high molecular weight complexes (Bhattacharyya and Das, 1999).

186 Besides, following the oral ingestion of dairy products including milk, fermented milk, cheese, and
187 yoghurt β -casomorphins are formed from β -CN. These peptides, acting as ligands to opioid
188 receptors generating an analgesic effect (Chabance et al., 1998; Woodford, 2021; Thiruvengadam
189 et al., 2021). In 2009 European Food Safety Authority stated that there are no health risks associated
190 with the eptapeptide β -casomorphin-7 (BCM7; EFSA, 2009).

191 κ -CN shows, due to its calcium solubility, play the role of casein micelle stabilization preventing their
192 precipitation in milk. Two peptides κ -CN are casoxins and casoplatelin which possess opioid
193 antagonist and platelet aggregation, respectively. This casein is highly sensitive to proteolysis by
194 chymosin and pepsin (Farrell et al., 2004; Delfour et al., 1965) cleaving κ -CN at the Phe105-Met106
195 peptide bond and releasing highly soluble caseinomacropeptide (CMP; with several the
196 carbohydrate residues such as fucose, galactose, N-acetylglucosamine, N-acetyl-galactosamine and
197 N-acetylneuraminic acid) and insoluble para- κ -casein. CMP shows, in vitro, several biological

198 activities, including neutralization of enterotoxin, inhibition of bacterial and viral adhesion to Caco-
199 2 cells, promotion of bifidobacterial growth and modulation of the immune system response
200 (Karimidastjerd and Gulsunoglu-Konuskan, 2021).

201 α_{s2} -casein which possesses two cysteine residues plays important role in the transport of calcium
202 phosphate. Its anti-microbial peptide casocidin-I has the ability to inhibit growth of *E. coli* and other
203 bacteria (Brignon et al., 1977; López-Expósito et al., 2006).

204 Phosphopeptides (CaseinoPhosphoPeptides, CPP) are released from casein, following enzymatic
205 hydrolysis of the casein fractions κ -, α_{s1} -, α_{s2} -, and β -CN (2). They are characterized by a consensus
206 sequence of the type SerP-X-SerP/ThrP/Glu/Asp, where X is any amino acid residue except Pro and
207 do not contain phosphorylated tyrosine and histidine residues. A sequence common to the α_{s1} -,
208 α_{s2} -, and β CN moieties is -Ser(P)-Ser(P)-Ser(P)-Glu-Glu-. CPPs are interesting because they survive
209 the gastrointestinal passage and are found in the stomach, duodenum and distal ileum after
210 ingestion of milk. They act as carriers of di- or trivalent mineral cations, increasing their
211 bioavailability for absorption in the small intestine. In fact, it has been demonstrated that CPPs, in
212 particular the peptides f(1-25)4P of β -casein and f(59-79)5P of α_{s1} -casein, increase calcium uptake
213 in differentiated human tumor cells enterocytic (HT-29), in Caco2 cells (8), and in osteoblasts (9).
214 These data have suggested the possibility of using CPPs as vectors of Ca^{2+} in functional foods to
215 increase their bioavailability in the development of the organism, in bone calcification and in the
216 prevention of osteoporosis (Clare and Swaisgood, 2000, Korhonen et al., 1998; Latham, 1999).

217

218 **4. Cow's milk allergenicity (CMA)**

219 Cow's milk allergy (CMA) is one of the most common food allergies in infants, and its prevalence has
220 increased over recent years (Flom and Sicherer, 2019; Mousan and Kamat, 2016). CMA is defined as
221 a reproducible adverse reaction to one or more cow's milk (CM) protein and it has a range of clinical
222 manifestations, with variable intensity and time, which can differ from "immediate" to "delayed"
223 reactions, reflecting the different pathogenesis (Giannetti et al., 2021). According to the definitions
224 issued by the European Academy of Allergy and Clinical Immunology and the American National
225 Institute of Allergy and Infectious Diseases, the CMA can be classified based on the underlying
226 immune mechanism into three categories: immunoglobulin E (IgE) mediated (IgE-CMA), non-IgE
227 mediated, and mixed (Boyce et al., 2011). About 60% of CMA are IgE-mediated, although estimates
228 change according to the study population and age (Flom and Sicherer, 2019). The remaining 40% is
229 divided into non IgE-mediated and mixed forms. In **figure 1** are schematized the main factors
230 accounting for a IgE food allergy.

231 Allergens present in the serum fraction, which represent approximately 20% of total proteins,
232 include α -lactalbumin (Bos d 4) and β -lactoglobulin (Bos d 5), which are the most abundant, and
233 immunoglobulins (Bos d 7), serum albumin (BSA, Bos d 6), and traces of lactoferrin, lysozyme,
234 proteose-peptone, and transferrin. The remaining 80% of milk proteins including casein fraction,
235 was globally indicated according to the official allergens nomenclature as Bos d 8
236 (<http://allergen.org/index.php>). Later on, each casein was classified with its own allergen code: α_{s1} -
237 casein, which is the most important as Bos d 9, α_{s2} -casein as Bos d 10 and β -casein as Bos d 11 and
238 κ -casein as Bos d 12.

239 Most children with milk allergy are sensitized to more than one protein, with a greater variability of
240 symptoms. Typically patients are sensitized to caseins (Bos d 8), β -lactoglobulin (Bos d 5), and α -
241 lactalbumin (Bos d 4), which are the major milk allergens. **Table 1** and **Figure 2** provide a short
242 description of linear epitopes located along the entire length of each casein subunit, the epitopic
243 sequences and the overlapping regions.

244

245

246 *4.1. CMA prevalence and diagnosis*

247

248 CMA usually occurs in the first two years of life and may resolve spontaneously during childhood or
249 adolescence (Giannetti et al., 2021). Currently, there is a significant heterogeneity in the prevalence
250 data of CMA in the majority of papers, ranged from 1.8% to 7.5%, depending on differences in study
251 design or methodology or differences between populations and geographic areas (Savage and
252 Johns, 2015; Giannetti et al., 2021). Moreover, many investigations assessing prevalence relies on
253 self-reports, with the consequent limitations linked to the subjective nature of the data (Savage and
254 Johns, 2015).

255 CMA diagnosis is based on the combination of clinical history and physical examination by allergy
256 tests such as specific IgE (sIgE) blood assay and skin prick test (SPT), and, when eligible, oral food
257 challenge (OFC). It is important to emphasize that sensitization, i.e., raised sIgE directed against a
258 specific antigen or positive SPT, in the absence of a supporting clinical history, is common in the
259 general population but insufficient for a diagnosis of CMA. A precise evaluation would require a
260 confirmatory oral food challenge (OFC) at predetermined intervals over time, however, such studies
261 are rarely conducted due to their intrinsically reduced feasibility and ethical issues (Savage and
262 Johns, 2015; Arasi et al., 2022).

263 Despite these limitations during the assessment, a large number of investigation have attempted to
264 estimate the prevalence of CMA. The results of two main contributors to such data by meta analysis
265 were reported in **table 2**. These meta-analyses show that prevalence estimates can be influenced
266 by many factors such as geographic region, source population, age and participation rates, and
267 limitations of diagnosis (Rona et al., 2007, Nwaru et al., 2014).

268 An important contribution to prevalence studies was the EuroPrevall birth cohort study, published
269 in 2015 (Schoemaker et al., 2015). In this study 12,049 children from across nine European centres
270 from different climatic and cultural regions were studied to generate the first reliable, multinational
271 incidence data on CMA. 9336 (77.5%) were followed up until the age of 2 years. They showed that
272 the incidence of CMA across Europe in the first two years of life was 0.74% (95% CI 0.56–0.97%),
273 ranging from 0.00% to 1.29% across the centres, with most affected infants having IgE-associated
274 CMA (incidence of 0.59%, 95% CI 0.43–0.80). CMA has a good prognosis with two-thirds of affected
275 infants becoming tolerant within one year after diagnosis. This tolerance development differed
276 according to the presence of sIgE to cow's milk: 57% of children with IgE-associated CMA tolerated
277 cow's milk and 100% of children with non-IgE-associated CMA.

278 Numerous papers have analyzed the possibility of establishing a cutoff for sIgEs and SPTs for CM
279 and its proteins that could predict whether a patient would react to an OFC. Indeed, it has been
280 demonstrated that the greater the food sIgE levels are and the SPT wheal size is, the higher the

281 chances that the patient will manifest adverse reactions during an OFC (Cuomo et al., 2017).
282 Actually, several studies showed that cutoffs can vary with age (Komata et al., 2007, Nowak-
283 Wegrzyn et al., 2009), with the type of allergen used to perform SPTs (commercial extract vs raw
284 milk) or because of the degree of cooking (Sampson et al., 2014).
285 Although OFC remains the gold standard for the diagnosis, data show that OFC results are not
286 predictive of the severity of subsequent reactions (Pettersson, 2018) and there is no direct
287 correlation between the eliciting threshold experienced by children during an OFC and the
288 reaction's severity upon accidental exposure (Eigenmann et al., 2021). Serious reactions to the OFC
289 have been described, up to a case of fatal reaction (Arasi et al., 2022). Therefore, predictors of the
290 OFC outcomes and alternative diagnostic tests are under investigation. Among these, the basophil
291 activation test (BAT) has been shown to provide some insights to distinguish patients who are
292 clinically allergic from those who are tolerant albeit sensitized (Santos et al., 2014, Rubio et al., 2011)
293 and potentially to support the risk stratification assessment for the severity of allergic reactions
294 (Santos et al., 2020, Kawahara, 2019). However, routine applications of BAT for clinical use are not
295 yet feasible due to the lack of standardized protocols and large clinical validation studies.

296

297 *4.2. Casein allergenicity*

298 Casein subunits (S1-casein, α -S2-casein, β -casein and κ -casein) induce different allergic responses
299 (Jaiswal and Worku, 2022). Among these subtypes, α -CN is reported as the most allergenic protein,
300 followed by κ -CN (Natale et al., 2004). The composition and sequence of amino acids determine the
301 higher structure of proteins and it is responsible for the biological function as well as allergenicity
302 of proteins (Zhao et al., 2023). To this regard the advancement in bioinformatics technology allows
303 to resolve the primary structures of many proteins and to predict functional proteins (Zhang et al.,
304 2017), active peptides (Auestad and Layman, 2021; Tondo et al., 2019; Gambacorta et al., 2022),
305 and adverse effects (Wang et al., 2020a). Today, databases with allergenic proteins and their
306 aminoacid sequence responsible for allergenic response are available and constantly updated (e.g.,
307 DNASTAR Protean, BepiPred1.0, ABCpred, IEDB, and NetMHCIIpan-4.0 server; Zhao et al., 2023;
308 Sarkar, et al., 2023). To provide an overview of casein allergenicity, epitopes and their reactivity by
309 each casein subunits are briefly discussed in the following sections.

310

311 *4.2.1 α -S1- casein (Bos d 9)*

312 Among casein subtypes, α -casein fraction is the most allergenic protein, followed by κ -casein (Natale
313 et al., 2004). Indeed, it was found that approximately 50% of serum samples from patients with cow
314 milk allergy react with α -S1-casein (Natale et al., 2004). Since the IgE-binding capacity is strongly
315 dependent on epitope sequence, a number of studies have been tailored to identify the IgE-binding
316 regions of α -S1-casein in humans. Grounding on the base that caseins don't have a rigid tertiary
317 structure but develop a random coil conformation stabilized by hydrophobic interactions, it should
318 be supposed that caseins show preferentially linear epitope. In 1998 Nakajima-Adachi and co-
319 workers investigated the determinants of IgE, IgG4, and T cells specific for bovine α -S1-casein from
320 patients by using its synthetic peptides and cyanogen bromide-digested fragments. By means of
321 ELISA for epitope mapping, an immunodominant IgE-binding region at the C-terminal (residues 181
322 to 199) was identified, while sites for anti- α s1-casein IgG4 were found to be located in multiple

323 regions of α -S1-casein (Nakajima-Adachi et al., 1998). In addition, Spuergin and others (1996), by
324 using a screening approach based on synthetic peptides, identified 3 immunodominant B-cell
325 epitopes of bovine α -S1-casein corresponding to amino acids 19-30, 93-98, and 141-150. Anyway
326 the reactivity of other parts of the proteins was observed when the sera of allergic patients were
327 singly analyzed (Spuergin et al., 1996). In 2001 Chatchatee and others identified 6 major IgE-binding
328 regions suggesting that there is a difference in epitope recognition between patients with persistent
329 and transient cow milk allergy (Chatchatee et al., 2001), while Cong and others in a study dated
330 2012, identified 4 different epitopic regions of α -S1-casein, with the recognition of the critical
331 residue for IgE-binding (Cong et al., 2002). More recently, Ruiter and others (2006) identified four
332 main regions (amino acid residues 43–66, 73–96, 91–114 and 127–180) in the α -S1-casein molecule
333 immunogenic to T cells, among which the amino acid residues 133–156 spanned the
334 immunodominant part (Ruiter et al., 2006). Interestingly, Yang and others demonstrated that the
335 digestion and transport characteristics of milk proteins, along with the epitope peptides release,
336 strictly depend from the dairy processing, indeed by investigating 3 commercial dairy products,
337 (pasteurized milk, ultra-heat-treated milk and dried skim milk) they found that only 2 peptides of α -
338 S1-casein (AA 84-90 and 125-132) of pasteurized milk and ultra-heat-treated milk persist after
339 gastrointestinal digestion and transportation via an Ussing chamber (Yang et al., 2022).
340 In the Immuno Epitope Database and Analysis Resource online platform (IEDB,
341 <https://www.iedb.org>) all the B cell and T cell epitopes currently identified for a multitude of
342 allergens are listed, and regarding α -S1-casein of cow milk (*Bos taurus* ID 9913), a total of 245
343 epitopes able to trigger allergenic reaction to humans were reported. In **figure 2** the sequential
344 linear epitopes located along the entire length of the allergen molecules is shown, while in **table 1**
345 the aminoacid sequence of the sequential epitopes along with additional information, such as the
346 mapped position in the protein sequence (start and end point), the number of epitopes substring or
347 those spanning between two adjacent regions, was displayed. Of 245 IgE-binding epitopes
348 recognized for cow milk α -S1-casein allergen, 212 are specific for B-cell and 43 for T-cell. It was
349 recently demonstrated that the genetic polymorphisms of caseins influence the allergenic potential
350 of some immunodominant epitopes. Indeed, single amino acid substitutions or deletion resulted in
351 a loss or decrease or increase in immunoreactivity in some α S1- and β -casein epitopes according to
352 RepliTop analysis performed using allergenic patients' sera (Lisson et al., 2013). Furthermore, it was
353 observed that goat and water buffaloes milk harbor an allergenic potential due to cross-reactivity
354 between cow and these species proteins, although individual epitopes from goats and water
355 buffaloes showed lower immunoreactivity compared with epitopes from cows, suggesting a
356 reduced allergenic activity of α -S1-casein from goat (Lisson et al., 2013).

357

358 4.2.2 α -S2- casein (*Bos d 10*)

359 α -S2- casein fraction of cow milk counts for approximately 12.5% of the whole casein proteins and
360 four different genetic variants (A, B, C and D) were identified with each of them showing different
361 structural characteristics (Villa et al., 2018). A sequence similarity of 90.1%, 54% and 58% was
362 observed in α -S2- casein of goat, camel and mare milk, respectively, when compared with cow milk
363 (Zhao et al., 2023). According to Natale and co-workers, the prevalence of sensitization to α -S2-
364 casein in patients with cow milk allergy is 90% (Natale et al., 2004) and four major and six minor

365 sequential IgE-binding regions were identified on this protein (Busse et al., 2002). The first major
366 region is located in the middle of the protein at amino acids (AA) position 83-100, while the other
367 three major regions are located in the carboxy terminal portion of the protein at AA 143-158, 157-
368 172 and 165-188. Minor IgE-binding regions were also identified at AA 31-44, 43-56, 93-106, 105-
369 114, 117-128, and 191-200 (Busse et al., 2002). Interestingly, the epitopic sequence
370 ¹⁷¹YQKFALPQYL¹⁸⁰ was recognized as a marker of persistent cow milk allergy (Järvinen et al., 2002).
371 More recently Cerecedo and others (2008) investigated the IgE- and IgG-binding areas of α 1-, α 2-
372 , β -, and κ -caseins and b-lactoglobulin in a population of patients by mean of a peptide microarray-
373 based immunoassay. The authors found 7 peptide sequences of α -S2-casein recognized by more
374 than 75% of patients, six of which never reported in literature before (Cerecedo et al., 2008). Finally,
375 in an interesting study of Yang et co-workers (2022), it was observed that, after gastrointestinal
376 digestion of pasteurized milk and ultra-heat-treated milk and transportation of the release products
377 in Ussing chamber, 1 peptide (AA 25–32) of α -S2-casein still survive, thus demonstration that
378 although processed, dairy products retain their allergenicity (Yang et al., 2022). By the IEDB online
379 platform it is possible to retrieve all the epitopic sequences currently identified for α -S2-casein of
380 different species. Regarding cow milk, 68 epitopes were reported and 10 sequential IgE binding
381 sequences approximately covering the whole proteins were found (**figure 2**). In **table 1** all the
382 relevant information about the mapped position of the sequential epitopes along with the epitope
383 substring and overlapping among the different protein regions are also reported. All the sequences
384 listed in IEDB database are recognized as linear B-cell epitopes.

385

386 4.2.3 β - casein (*Bos d 11*)

387 Among cow milk proteins, β - casein represents the second highest fraction constituting the 34.13%
388 of the total content of caseins. A different situation could be observed for other species where the
389 concentration of β - casein is the first highest among all proteins, such as in human (69%), goat
390 (55%), camel (65%) and mare (79%) (Zhao et al., 2023). A total of thirteen-casein genetic variants
391 have been identified in β - casein of cow milk, including A1, A2, B, C, D, E, F, H1, H2, I and G showing
392 changes in aminoacid sequence that led to different level of phosphorylation (Kaminski et al., 2007;
393 Caroli et al. 2002; Petrat-Melin et al., 2015). The genetic variants of bovine β -casein have drawn a
394 special interest and attention to scientist and dairy consumers due to the potential relationship
395 existing between the β - casein genotype and the health of cow's milk consumers. A1 and A2
396 represent the most common forms of β - casein in dairy cow breeds, whereas B variant is less
397 common, and A3 and C alleles are rare (Giglioti et al., 2020). The difference between A1 and A2
398 bovine relies in an amino acid substitution at the 67th position of the protein chain, where it is
399 possible to find an histidine in A1 milk and a proline in A2 milk (Heyman et al., 1988). During human
400 digestion A1 bovine milk proteins was found to release the peptide beta-casomorphin-7 (BCM-7)
401 that has shown to be the primary causative factor for health and digestive disorders associated with
402 A1 milk, such as cow milk protein allergy (Caroli et al., 2009). On the contrary, the presence of a
403 proline residue in A2 β -casein prevent the breakdown of the sequence at position 67 so that
404 another peptide called BCM-9 is generated. Interestingly, no relationship has been found between
405 the presence of A2 β -casein in the milk and cow milk protein allergy (CMPA) or health problems

406 (Sun et al., 1999). In the light of this the A2 cow milk has emerged and recommended for remedy to
407 cow milk allergy.

408 A recent investigation of Lisson and others (2014) highlighted that genetic polymorphisms of bovine
409 caseins influence the allergenic potential of some immunodominant epitopes, indeed by peptide
410 microarray-based immunoassay, the authors found variation in IgE binding for peptides AA 103 to
411 123 and AA 108 to 129 of 3 β -CN variants A1, A2, and B although in some cases the IgE response
412 was patient-dependent (Lisson et al., 2014).

413 Regarding β - casein allergenicity, on IEDB online platform a total of 126 linear B-cell epitopes are
414 so far reported for bovine. In 2001 Chatchatee and others identified six major and three minor IgE-
415 binding epitopes, as well as eight major and one minor IgG binding regions, on β - casein sequence
416 (Chatchatee et al., 2001). On the other hand, Cerecedo et co-workers (2008) by using peptide
417 microarray-based immunoassay, identified four main sequential epitope, namely
418 ¹³⁶ESQSLTLTDVENLHLPLLL¹⁵⁵, ⁶⁷FAQTQSLVYPPFGPIPNLSLPQNI⁸⁹,
419 ⁴⁰RINKKIEKFQSEEQQTDELQDKIH⁶⁵, and ¹⁶⁹TVMFPPQSVLSLSQSKVLPV¹⁸⁸ which showed
420 differential recognition patterns between patients reactive and tolerant to cow milk allergy
421 (Cerecedo et al., 2008). In **figure 2** the sequential linear epitopes covering the whole protein are
422 listed, while in **table 1** the most relevant information about these epitopes location along with the
423 substring/overlapping epitopes are reported.

424

425 4.2.4 κ -casein (*Bos d 12*)

426 κ -casein counts for approximately 13% of the cow milk casein fraction and together with α -casein
427 represents the major allergenic subtypes of caseins in cow milk (Natale et al., 2004). It is the only
428 glycosylated casein containing galactose, galactosamine and sialic acid and, on the base of the
429 degree of glycosylation, multiple isoform of κ -casein can co-exist in milk (Villa et al., 2018). To date,
430 11 variants of these proteins have been observed (Fox et al., 2001, Farrell et al., 2004). Regarding
431 its allergenicity, in a first report describing the allergenic epitopes of bovine β - and κ -casein
432 recognized by allergic individuals, eight major IgE-binding epitopes, as well as two major and two
433 minor IgG-binding epitopes, were detected on kappa-casein (Chatchatee et al., 2001). Specifically,
434 by using overlapping synthetic peptides and sera from cow milk allergenic patients, the authors
435 identified 3 major epitopes recognized by 93% of patients' serum samples, namely
436 ⁹IRCEKDERFFSDKIAKYI²⁶, ²¹KIAKYIPIQYLLSRYPYGLNYY⁴⁴, and ⁴⁷KPVALINNQFLPYPYAKPAAVR⁶⁸),
437 and 6 epitopes by the majority of older patients (Chatchatee et al., 2001). 2 additional dominant
438 epitopes were identified by Cerecedo and others (2008), namely ¹⁶RFSDKIAKYIPIQYVLSRY³⁵ and
439 ³⁴RYPYGLNYYQKPVALINN⁵³ (Cerecedo et al 2008). Interestingly, Järvinen et co-workers in 2002
440 observed that there is an IgE-binding epitope of κ -casein, namely ¹⁵⁵SPPEINTVQV¹⁶⁴, typical of patients
441 with persistent cow milk allergy, indeed no IgE signals were observed when children affected by
442 transient cow milk allergy were tested, thus suggesting the possibility to use this allergenic epitope
443 as a screening instrument for persistent cow milk allergy (Järvinen et al., 2002). Moreover, taking
444 into account that the allergenicity is strictly related to the aminoacid sequence and that any
445 eventual residue substitution of the native residues by others could affect the overall loss/decrease
446 of IgE-binding, Han and others (2008) identified a total of 13 aa (at positions 17, 18, 29, 32, 35, 58,
447 61, 72, 97, 105, 118, 146, and 160) as critical residues for IgE-binding to linear epitopes of κ -casein.

448 Indeed, by testing several synthesized peptides representing the IgE-binding epitopes of κ -casein
449 with single AA substitutions at each position, they found that for 10/11 allergenic peptides, one to
450 five different single AA substitutions resulted in elimination of IgE-binding of pooled patient sera
451 (Han et al., 2008). Finally it was reported that cow milk κ -casein show a 61% homology with human
452 milk, with the three most frequently recognized Ig-E epitopes, namely AA 9-26, AA 21-44 and AA
453 47-68 showing a 53%, 67% and 64% homology, respectively, with human κ -casein. Taking into
454 account that the degree of homology between certain food antigens and human proteins
455 may have some influence on the sensitization and development of allergy to certain food
456 proteins, the high degree of homology between cow and human κ -casein could explain the high
457 allergic potential of these antigenic peptides for human (Chatchatee et al., 2001). By searching on
458 the IEDB on-line platform, a total of 125 B-cell epitopes are currently listed and as observed for
459 other casein proteins, approximately all the protein sequence retains sequential epitopes (**figure 2**).
460 In **table 1** all the information about the sequential epitopic peptides and other relevant information
461 are reported.

462

463 **5. Milk processing strategies to mitigate casein allergenicity**

464 Allergenicity reduction is currently attracting the interest of the reasearch activity in order to
465 produce foods with a decreased allergenic potential that should undergo appropriate clinical assays
466 (e.g. oral food challenge tests) before claiming to be safe for allergic individuals.

467 The processing applied to mitigate allergenic potential is divided in two subcategories: thermal and
468 non-thermal treatments, depending if heating (moist or dry) is applied or not (Shriver and Yang,
469 2011). Thermal processing can be effective on the food protein but may also impact the sensory and
470 nutritional value of the food. Growing consumer demands for minimally processed and fresh-tasting
471 foods have therefore driven the rapid development of novel non-thermal food processing
472 technologies (Dong et al., 2021). **Figure 4** illustrated the potential paths/ mechanisms of attenuation
473 of food allergenicity by means of thermal and non-thermal methods. Non-thermal processing
474 technologies such as cold atmospheric pressure plasma, pulsed ultraviolet light, gamma-irradiation
475 or high pressure, which can induce changes in proteins and potentially mitigate allergenicity while
476 retaining the organoleptic properties of food, are currently being investigated (Ekezie et al., 2018).
477 Some of them (such as HPP, short-wavelength electromagnetic gamma (g)-irradiation) also turned
478 out to be an effective preservation method, extending the shelf-life of perishable foods (Kasera et
479 al., 2012).

480

481 *5.1 Heat based treatments*

482 Depending on whether water is used to convey heating, thermal food preparation methods could
483 be split in two sub-groups, “moist heat treatments” and “dry heat treatments” with pasteurization
484 and sterilization being the two temperature ranges generally adopted for these treatments.
485 Considering the impact of thermal treatments on the native structure of proteins, the effects of
486 these methods on the finally allergenicity of foods could be very different, varying from a mitigation
487 of allergenicity to a significant increase of it (Cabanillas and Novak, 2019). As known, proteins have
488 a native structure which stability depends on hydrogen bonds, disulphide bonds, electrostatic, and

489 hydrophobic interactions (Davis and Williams, 1998). When the heat energy is applied, the
490 molecular bonds that hold the allergen protein structures together tends to modify themselves thus
491 the proteins slowly starts to lose its native structure.

492 Taking into account that conformational epitopes are associated to secondary protein structure, it
493 is reasonable to assume that they are more labile to this processing methods than linear epitopes
494 and, therefore, more likely to be disrupted under harsh conditions (Cabanillas and Novak, 2019). In
495 the light of this, if a reduction in the final allergenicity of food could be expected after thermal
496 processing (masking or destruction of epitopes), in practice controversial results were reported on
497 the use of heating to alter the immunological potential of some allergens. Indeed, along with the
498 numerous studies proving the efficacy of thermal processing to reduce the allergenicity of foods
499 (reviewed by Cabanillas and Novak, 2019; Vanga et al., 2017), there are some investigations where
500 an increase in the IgE reactivity of a certain proteins (exposure of epitopes or generation of new
501 ones) or no change in it (allergen stability) were observed (Van der Ventel et al., 2011; Carnés et al.,
502 2007; Abramovitch et al., 2013; Pastorello et al., 2010).

503 The effect of thermal processes on the final allergenicity of food depend on the temperature, type,
504 and duration of the treatment, as well as of the intrinsic characteristics of the protein and of the
505 physicochemical conditions of its microenvironment (Mills et al., 2009; Wal, 2003).

506 Several studies demonstrated that both the heating and the food matrix e.g. in the baking process
507 could result in a reduction of allergenic potential of milk containing foods demonstrating to be
508 tolerated by patients allergic to milk (Leonard et al., 2016, Bavaro et al., 2019). As reported by
509 Leonard et al. (2016) in baked form, cow's milk is less allergenic and is tolerated by most milk-allergic
510 children. Not only, may including baked milk in the diets of children who are tolerant improve
511 nutrition and promote more social inclusion but there is also evidence that inclusion may accelerate
512 the resolution of unheated milk and egg allergy. In a recent study it has been reported that milk
513 baked within the muffin matrix might promote formation of complexes with food components
514 inducing a modulation of the immunoreactivity towards milk allergens compared to milk baked in
515 the oven at 180 °C for ten minutes. The interactions between milk proteins and some components
516 of the food matrix during heating seemed to play a role in the possible reduction of allergenicity as
517 assessed by in vitro tests (Bavaro et al., 2019).

518

519 *5.2 Non heat treatments*

520 Among the non heating treatments the following will be presented: 1. High Hydrostatic Pressure
521 High hydrostatic pressure (HHP), 2. Cold Atmospheric Plasma (CAP), 3. Food Irradiation (FI), 4.
522 Ultrasound treatment (UT), 5. Enzymatic Hydrolysis (EH)

523 High Hydrostatic Pressure High hydrostatic pressure (HHP) processing has shown enormous
524 potential in the application to the food industry to inactivate spoilage microorganisms and enzymes
525 while preserving sensorial properties and nutritional values of foods (Zhu et al., 2022; Aganovic et
526 al., 2021). HHP typically employs pressures ranging from 100 to 800 MPa at moderate or elevated
527 temperatures. Water is used as the pressure transfer medium, and the pressure is transmitted
528 instantaneously and uniformly throughout the food system regardless of its size and shape. Since
529 the first discovery in 1914 (Bridgman, 1914) of coagulation phenomena occurring on egg albumen
530 submitted to HHP, high pressure has been applied as a robust tool for probing changes in the

531 structure and properties of proteins, in the fields of biophysics, chemistry, microbiology, and food
532 technology (Meersman and McMillan, 2014; Teixeira et al., 2014). It is likely that under pressure
533 treatments, protein chains will unfold and oligomeric proteins will disassociate (Le Vay et al., 2020).
534 Upon decompression, the altered protein structure may not recover as a result protein properties
535 are modified (Roche and Royer, 2018). HHP applied to allergenic food ingredients can induce
536 changes of the noncovalent bonds and for this reason it has been recently investigated as a
537 technique capable of reducing the allergenic potential of different foods (Cuadrado et al., 2020;
538 Huang et al., 2014; Pan et al., 2020). Allergenicity reduction induced by HHP can be due to several
539 reasons through application of high pressure: (1) increase the penetration of surrounding solution
540 into food when the food undergoes the HHP immersed into a liquid medium through the extraction
541 of allergens contained in food; (2) irreversible or reversible modification of protein structures
542 caused by HHP that can also give rise to the gelatinization, aggregation, or denaturation of proteins
543 (Han et al., 2018; Bavaro et al., 2018; De Angelis et al., 2018, 2022). The aggregation of proteins may
544 mask or destroy the critical epitopes, often causing the reduction of allergenicity, although in some
545 cases can also promote production of neo-epitopes. Finally, HHP might cause conformational
546 changes of allergic protein then affecting the overall allergenicity. It should be underlined that HHP
547 only affects the weak bonds including hydrogen, ionic, and hydrophobic bonds thus exerting an
548 influence on the tertiary and quaternary structures maintained by noncovalent interaction. Such
549 changes in the structures might determine changes in the allergenicity of allergenic proteins

550

551 *5.3 Cold atmospheric plasma (CAP)*

552 Cold atmospheric plasma (CAP) has been used in the past mainly for sterilization of sensitive
553 materials and more recently also extended to food industries as a novel processing technology
554 offering increased safety profiles and extended shelf life for food products (Thirumdas et al., 2015).
555 It is considered as modern non-conventional technique used in the preservation of food and for the
556 preparation of modified starches, altering its physical and chemical properties. Its role is more
557 prevalent for application in microbiology as an alternative microbial inactivation technology due to
558 its germicidal effects while maintaining quality of fresh products (Thirumdas et al., 2015; Schlüter
559 et al., 2013). Given the technology's multimodal action it has the potential to reduce allergens in
560 foods, although data on the efficacy and mechanisms of action are not exhaustive. An hypothesis
561 for its mechanism of action is the ability of CAP to promote reactions in liquids by injecting reactive
562 oxygen radicals, altering the epitope structure. As for milk allergens, Tammineedi et al. (2013) used
563 cold plasma to treat casein, b-Lg and a-La founding no significant difference in the IgE binding values
564 between the control and treated samples. Conceivably, the poor plasma efficiency associated with
565 remote plasmas might be responsible for the absence of attenuation in immunoreactivity
566 (Tammineedi et al., 2013). On the contrary, in a recent study, casein, β -lactoglobulin and α -
567 lactalbumin analyzed before and after plasma treatment revealed alterations in the secondary
568 structure of the proteins with consequent decrease of antigenicity of casein and β -lactalbumin,
569 whereas α -lactoglobulin showed increased antigenicity (Ng et al., 2021).

570

571 *5.4 Food Irradiation (FI)*

572 Recent studies about food irradiation have demonstrated the reduction of allergenicity of foods
573 including shellfish, soy, peanut, milk, tree nut, egg, wheat and fish. Principles of food irradiation,
574 including mechanisms of allergenicity-reduction, irradiation types and characteristics have been
575 addressed and final conclusions that food irradiation is a safety tool to reduce the allergenicity of
576 food effectively, with high nutritional value and long shelf-life, making it a competitive alternative
577 technology to traditional techniques such as heating treatments (Pi et al., 2021). Irradiation was
578 found to improve the quality of milk, although modifications in proteins structure could occur. For
579 example, changes in the secondary and tertiary structure were observed in β -lactoglobulin (in
580 solution) subjected to γ -irradiation with consequent protein aggregation (De La Hoz and Netto,
581 2008). Moreover, a reduction in milk allergenicity due the destruction of human IgE-binding
582 epitopes was reported in treated milk, although the final results were dependent on the dose of
583 irradiation (Lee et al., 2001)

584

585 *5.5 Ultrasound Treatment (UT)*

586 To date, the effect of ultrasound treatment on the allergenicity of several foods has not been
587 extensively investigated. The high mechanical energy produced by high-intensity ultrasound causes
588 a cavitation effect, which results in the destruction of the protein spatial structure with an increase
589 of solubility and emulsifying properties and in the case of a reconstituted milk protein concentrate
590 (Sun et al., 2014). Given the connection between protein structure and allergenicity, it can be
591 inferred that ultrasound treatment could be effective in producing hypoallergenic cow's milk. In
592 another study reported by Wang et al. (2020b), casein (CN) proteins were purified from fresh milk
593 and the effect of ultrasound on the allergenicity of CN was investigated (Wang et al., 2020b). After
594 treatment, the authors demonstrated that IgE-binding capacity of CN was decreased, indicating that
595 the conformational epitopes were destructed. It was suggested that ultrasound treatment not only
596 destructed the epitopes but also decreased the oligomerization level of CN and, therefore,
597 significantly impaired the allergenicity of CN. This paves the way for optimizing a novel method for
598 the production of food with a decreased allergenicity. Similarly, Stanic-Vucinic and colleagues have
599 demonstrated that, when β -lactoglobulin was exposed to high-intensity ultrasound, a
600 conformational change occurred where the β -sheet converted to α -helix (Stanic-Vucinic et al.,
601 2012). However, no remarkable alterations in the sera IgE-binding reaction, basophil activation test,
602 and skin prick test of patients were observed after these conformational changes

603

604 *5.6. Enzymatic treatment*

605 Proteolysis offers an efficient way to destroy allergenic epitopes. To reduce their allergenicity,
606 proteins can be broken down by enzyme hydrolysis into small peptide molecules and amino acids.
607 Some food-grade proteinases have been used to manufacture whey protein hydrolysates with
608 reduced antigenicity (Quintieri et al., 2017). In the process of hydrolysis, the differences in the types
609 of enzyme, hydrolysis model and the degree of hydrolysis may result in some discrepancies in
610 peptide composition and residual antigenicity of the hydrolysate; this occurs due to the non-
611 specific hydrolysis of the epitopes by the proteases. Thus, new method to screen the efficacy of
612 proteases based on the detection of residual allergenic epitopes are currently investigated (Liu, et

613 al., 2022). Recently, sequential enzymatic hydrolysis catalysed by chymosin and papain with IgG-
614 binding inhibition was effective in reducing α 1-CN-antigenicity; this innovative approach
615 investigating enzymatic hydrolysis for reducing CN-antigenicity based on CN structure was
616 suggested promising to develop hypoallergenic CN hydrolysed infant formulas (Zeng et al., 2023).
617 Also fermentation induced by microorganisms such as *Lactobacillus spp. (LAB)* have been considered
618 to exhibit proteolytic activity toward milk proteins. During fermentation, proteases and peptidases
619 produced by LAB cleave milk proteins into peptides and amino acids. This proteolysis potentially
620 breaks some epitopes and consequently decreases the antigenicity and allergenicity of milk proteins
621 (Chobert, 2012, Meng et al., 2021, Yao et al., 2014). In particular, *L. plantarum* reduce cow's milk
622 protein allergenicity through the combination of cell-envelope proteinase and peptidase on α -CN. *L.*
623 *helveticus* is well-recognized for its high proteolytic activity and ability of releasing bioactive
624 peptides during milk fermentation (Gandhi and Shah, 2014). Besides, *L. helveticus* has proved to
625 effectively hydrolyze α 1-casein and β -casein into peptides, and decreased their IgE binding ability
626 (Ahmadova et al., 2011).
627 Synergistic effects of *Streptomyces* aminopeptidases belonging to the M1, M24, and M28 families
628 on the degradation of the allergen peptides were also demonstrated; in particular, the combination
629 of M1 and M24 aminopeptidases were effective to hydrolyze VLPVPQK and FFVAPFPEVFGK, from
630 bovine casein-derived allergen peptides (Wan et al., 2019).
631 Enzymatic crosslinking has the potential to alter the primary, secondary, and tertiary structure of
632 allergens by modification of specific amino acid residues and the formation of high molecular weight
633 polymerized allergens. Studies have shown that enzymatic crosslinking caused the loss of secondary
634 structure of food allergens and unfolded the tertiary structure (Ahmed et al., 2020; Fei et al., 2016).
635 Modification of the secondary and tertiary structures of food allergens are the main factors involved
636 in the reduction of food allergenicity due to the reduced binding propensities to their specific IgE
637 antibodies (Ahmed et al., 2018). Enzymatic crosslinking of caseins has been also shown to affect the
638 allergenic properties has been reported (Stanic et al., 2010). Stanic et al., (2010) investigated in vitro
639 the residual allergenicity of β -CN crosslinked by transglutaminase, tyrosinase, mushroom
640 tyrosinase/caffeic acid and laccase/caffeic acid. Among the assayed peptides, laccase/caffeic acid
641 and mushroom tyrosinase/caffeic acid had the highest potential in mitigating IgE binding and
642 allergenicity of the β -CN out of all investigated enzymes.
643 Few researches has been published on the impact of different crosslinking enzymes on milk
644 allergenicity (Ahmed et al., 2021).; most reported studies include whey proteins and, however, more
645 clinical trials need to be still performed.

646

647 **6. CMA prevention, management and therapeutic approaches**

648 Family history of allergy-associated diseases is the most important risk factor for allergy
649 manifestations in the offspring. Primary prevention strategies could be applied in high-risk infants
650 defined as those with a first-degree relative with a history of allergy (Trogen et al., 2022).
651 Primary prevention of CMA should start from pre-pregnancy with a focus on a healthy lifestyle and
652 food diversity to ensure adequate transfer of inhibitory IgG- allergen immune complexes across the
653 placenta especially in mothers with a history of allergic diseases and planned c-section delivery. For
654 non-breastfed infants, there is controversy about the preventive role of partially hydrolysed

655 formulae (pHF) despite some evidence of health economic benefits among those with a family
656 history of allergy.

657 Clinical management of CMA consists of secondary prevention with a focus on the development of
658 early oral tolerance. Preventing disease progression from mild or moderate symptoms to severe
659 symptoms or another allergy phenotype in children with CMA is considered as secondary prevention
660 and management of CMA

661 The use of extensive Hydrolysate Formulae (eHF) is the nutrition of choice for the majority of non-
662 breastfed infants with CMA as summarized in **Figure 4**; potentially with pre-, probiotics and LCPUFA
663 to support early oral tolerance induction. Future opportunities are, among others, pre- and
664 probiotics supplementation for mothers and high-risk infants for the primary prevention of CMA. A
665 controlled prospective study implementing a step-down milk formulae ladder with various degrees
666 of hydrolysate is proposed for food challenges and early development of oral tolerance. This
667 provides a more precise gradation of milk protein exposure than those currently recommended.

668 The standard treatment of CMA relies on CM avoidance. Breastfeeding is the best source of nutrition
669 for nearly all infants and at all times it should be supported in children with CMA. Breastmilk
670 contains a series of inimitable molecules with potential immune-modulating activities, including the
671 establishment of gut microbiota, the prevention of overweight and obesity, the development of
672 immunoallergic parameters and the neural development (Agostoni et al., 2009).

673 Breastfeeding is the first choice for infants with CMA. However, the suggestion of CM elimination
674 diet for mothers breastfeeding allergic infants is a peculiar issue that needs to be confirmed in an
675 evidence-based manner and evaluated on individual basis.

676 If breastmilk is unavailable, it is required a hypoallergenic formula, i.e. an industrially produced
677 substitute highly controlled for nutritional content and tolerance in CMA infants. In the past 10
678 years, formulas in the CMA management have been profoundly expanded, with extensively
679 hydrolysed formulas (eHFs) (Strozyk et al., 2020), rice hydrolyzed formula (HRF) (Vandenplas et al.,
680 2014), amino acid formulae (AAF) (Fierro et al., 2020), camel and dromedary milk (Navarrete-
681 Rodriguez et al., 2018), and donkey milk (Monti et al., 2012).

682 Choosing the most appropriate formula for each infant should be based on clinical presentation,
683 nutritional composition, and residual allergenicity of the proposed hypoallergenic formula.

684 EHF and AAF are valid alternatives. Heed is needed to ensure the formula is nutritionally sufficient.
685 CM-OIT and/or omalizumab may be effective by itself/themselves in improving the threshold of
686 reactivity to CM. There is currently stronger evidence for CM-OIT because of paucity of data on
687 omalizumab in FA but the current evidence is promising. In particular, omalizumab may be
688 considered if allergy to several food sources and concomitant allergic diseases.

689 After several decades of 'passive clinical managements', based only on avoidance of CM products
690 and the use of epinephrine in the event of anaphylaxis, there has been a switch to active treatment.
691 The most recent evidence-practice guidelines strongly recommend the use of CM-OIT as an effective
692 therapeutic option in persistent CMA (Pajno et al., 2018).

693 CM-OIT consists of providing gradually increasing doses of CM (up-dosing phase) up to a
694 maintenance dose that will be continued (maintenance phase) with the goal of inducing
695 desensitization (i.e. increasing the threshold of reactivity while in treatment) (Wood, 2017). Several
696 protocols have been evaluated, with the most notable examples being the weekly (Pajno et al.,

697 2018), or slow up-dosing regimens (Kaneko et al., 2010), the rapid oral desensitization combined
698 with omalizumab (different maintenance feeding regimens (Nadeau et al., 2011; Pajno et al. 2013)
699 and baked CM-OIT (Dantzer et al. 2022; Goldberg, et al. 2015; Kim et al., 2011). Notwithstanding
700 the heterogeneity among studies, children with IgE-CMA seem to tolerate significantly more CM
701 while on therapy (Dang et al., 2016; Nurmatov et al., 2017; de Silva et al., 2022).

702

703 **Conclusions and future perspectives**

704

705 Caseins represent the main protein fraction of cow's milk. They have binding capacity, stabilizing
706 and emulsification activities, gelation and water binding capacity making them good candidates as
707 delivery systems for food and pharmaceutical applications.

708 Despite their valuable properties, caseins are also the major responsible of cow's milk allergy
709 especially in children. Strategies for allergenicity reduction have been put in place in order to
710 produce a final product that can be tolerated by allergic consumers. Baked milk demonstrated to be
711 well tolerated by allergics to be included in the diet of a majority of milk-allergic individuals/children;
712 more research is required to identify new thresholds for this category of patients by planning oral
713 food challenges.

714 More efforts, in perspective, should also be directed in identifying clinical factors and biomarkers
715 for predicting baked milk tolerability or reactivity as there is a lack of knowledge in this area and
716 more needs to be done. Also, to avoid exposing allergic patients to oral food challenge studies, the
717 use of alternative and less invasive approaches e.g. prick by prick test and allergen specific IgE assays
718 should be also sought for, as new diagnostic predicting tools.

719 In addition, thanks to the advanced bioinformatics tools and proteomic platforms so far available,
720 further research is needed for the identification of new antigenic determinants spread along casein
721 moieties and for the characterization of the neoantigens that might be formed upon processing in
722 the allergen containing food.

723

724

725

726

727

728

729

730

731

732

733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755




Figure 1. Main factors accounting for IgE mediated food allergy.

Alpha S1 casein bos taurus – Bos d 8/9

```
>sp|P02662|CASA1_BOVIN Alpha-S1-casein OS=Bos taurus OX=9913
GN=CSN1S1 PE=1 SV=2
MKLLILTCLVAVALARPKHPIKHQGLPQEVLNENLLRFFVAPFPEVFGKEKVNELSKDIGSESTED
QAMEDIKQMEAESISSSEEIVPNSVEQKHIQKEDVPSERYLGYLEQLLRLLKKYKVPQLEIVPNSAE
ERLHSMKEGIHAQQKEPMIGVNQELAYFYPELFRQFYQLDAYPSGAWYYVPLGTQYTDAPSFSDIP
NPIGSENSEKTTMPLW
```

Alpha S2 casein bos taurus – Bos d 10

```
>sp|P02663|CASA2_BOVIN Alpha-S2-casein OS=Bos taurus OX=9913
GN=CSN1S2 PE=1 SV=2
MKFFIFTCLLAVALA KNTMEHVSSSEESIISQETYKQEKMAINPSKENLCSSTFCKEVVRNANEEE
YSIGSSSEESAEEVATEEVKITVDDKHYQKALNEINQFYQKFPQYLQYLYQGPIVLNPWDQVKRNAV
PITPTLNREQLSTSEENSKKTVDMESTEVFTKKTKLTEEKKNRLNFKKISQRYQKFALPQYLKTV
YQHQA MKPWIQPKTKVIPYRYI
```

Beta casein – Bos d11


```
>sp|P02666|CASB_BOVIN Beta-casein OS=Bos taurus OX=9913 GN=CSN2
PE=1 SV=2
MKVLILACLVALALARELEELNVPGEIVESLSSEESITRINKKIEKFQSEEQQTEDELQDKIHP
FAQTQSLVYFPFGPIPNSLPQNIPPLTQTPVVVPPFLQPEVMGVSKVKEAMAPKHKEMPFPKYPVE
PFTESQSLTLTDVENLHLPLPLIQSWMHQHPQPLPPTVMFPPQSVLSLSQSKVLPVPQKAVPYPQR
DMPIQAFLLYQEPVLPVVRGPFPIIV
```

Kappa- casein – Bos d12

```
>sp|P02668|CASK_BOVIN Kappa-casein OS=Bos taurus OX=9913 GN=CSN3
PE=1 SV=1
MMKSFFLVVTILALTLPLFLGAQEQNQEQPIRCEKDERFFSDKIAKYIPIQYVLSRYPSYGLNYYQQ
KPVALINNQFLPYPYAKPAAVRSPAQILQWVLSNTVPAKSCQAQPTMARHPPHLSFMAIPPK
KNQDKTEIPTINTIASGEPTSTPTTEAVESTVATLED SPEVIESPPEINTVQVTSTAV
```

756
757
758
759
760
761
762
763
764
765
766
767

Figure 2. Linear epitopes located along the entire length of each casein subunit.




768

769

770 **Figure 3.** Imported from Monaci, et al., 2023. (Bio)technological Approaches for Reducing
 771 Allergenicity of Food Ingredients. In: Ferranti, P. (Ed.), Sustainable Food Science: A Comprehensive
 772 Approach, vol. 1. Elsevier, pp. 86–102.

773



774

775

776 **Figure 4.** Alternative hypoallergenic formula for infants in case of unavailability to breastfeeding

Antigen	Uniprot ID	Regions	Epitopic sequence	Mapped start-end position (aa)	# epitopes substring	# epitopes overlapping two consecutive regions	Overlapping regions
α S-1 casein	P02662	1	RPKHPIKHQGLPQEVLNENLLRFFVAPFPEV	16-46	20	22	1-2
		2	FGKEKVNELSKDIGSESTEDQAMEDIKQMEAES	47-79	17	15	2-3
		3	ISSSEIIVPNSVEQKHQKEDVPSERYLGYLEQLLR	80-115	20	16	3-4
		4	LKKYKVPQLEIVPNSAEERLHSMKEGIHAQQKE	116-148	20	19	4-5
		5	PMIGVNVQELAYFPELFRQFYQLDAYPSGAWYYV	149-182	25	23	5-6
		6	PLGTQYTDAPSFSDIPNPIGSENSEKTTMPLW	183-214	36	\	\
α S-2 casein	P02663	1	KNTMEHVSSSEESIISQETY	16-35	\	1	1-2
		2	QEKMAINPSKENLCSTFCK	37-56	4	5	2-3
		3	VVRNANEEY	58-67	\	3	3-4
		4	SEESAEVATEEVKITVDDKH	73-92	\	5	4-5
		5	QKALNEINQFYQKFPQYLQY	94-113	4	9	5-6
		6	YQGPIVLNPWDQVKRNAVPI	115-134	1	6	6-5
		7	TLNREQLSTSEENSKKTVDM	137-156	\	\	\
		8	STEVFTKTK	158-167	\	4	8-9
		9	EKNRLNFLKKISQRYQKFAFPQYLKT	172-197	10	5	9-10
		10	MKPWIQPKTKVIPYVRYL	205-222	1	\	\
β -casein	P02666	1	RELEELNVPEIVESLSSE	16-29	5	9	1-2
		2	ESITRINKKI	36-454	\	5	2-3
		3	QSEEQQTEDELQDKIHPFA	49-68	4	12	3-4
		4	TQSLVYFPFG	70-79	\	7	4-5
		5	PNSLPQNIPP	82-91	\	4	5-6
		6	QTPVVVPPFLQPEVMGVSKV	94-113	\	5	6-7
		7	EAMAPKHKEMPFKYPVEPF	115-134	3	16	7-8
		8	ESQSLTLTDVENLHLPLLL	136-155	3	6	8-9
		9	QPLPPTVMFPPQ	164-175	2	5	9-10
		10	SVLSLSQSKV	176-185	\	7	10-11
		11	LPVPQKAVPY	186-195	\	7	11-12
		12	PQRDMPAQIFLLYQEPVLGP	196-215	7	7	12-end
κ -casein	P02668	1	QEQNQEPIRCEKDERFFSD	22-41	6	11	1-2
		2	KIAKYIPIQY	42-51	\	10	2-3
		3	VLSRYPSYGLNYYQKPVVAL	52-71	5	8	3-4
		4	INNQFLPYPY	72-81	\	8	4-5
		5	YAKPAAVRSPAQILQWQVLS	82-101	7	6	5-6
		6	CQAQPTTMRHHPHLSFMA	109-128	5	14	6-7
		7	PPKKNQDKTEIPTINTIASG	130-149	8	7	7-8
		8	EPTSTPTTEA	150-159	\	8	8-9
		9	VESTVATLED	160-169	\	6	9-10
		10	SPEVIESPPE	170-179	\	6	10-end

780

Reference	Publication years (N° of papers included in the meta-analysis)	Prevalence of CMA				
		Self-reported	SPT alone	slgE assay alone	symptoms and sensitization (SPT 3 mm or slgE > 0.35 kU/L)	OFC
Rona et al. (2007)	1990-2005 (51 papers)	1.2%-17%.	0.2%-2.5%	2%-9%,	0%-2%	0%-3%
Nwaru et al. (2014)	2000-2012 (42 papers)	2.3% (95% CI 2.1–2.5),	0.3% (95% CI 0.03–0.6)	4.7% (95% CI 4.2–5.1).		0.6% (95% CI 0.5–0.8)

781

782

783 **Table 2.** Meta-analysis results for estimating the prevalence of CMA.

784

785

786

787

788

789 **References**

- 790 Abramovitch, J.B., Kamath, S., Varese, N., Zubrinich, C., Lopata, A.L., O'Hehir, R.E., et al., 2013. IgE reactivity
791 of blue swimmer crab (*Portunus pelagicus*) Tropomyosin, Por p 1, and other allergens; crossreactivity with
792 black tiger prawn and effects of heating. *Plos One* 8(6), e67487.
- 793 Aganovic, K., Hertel, C., Vogel, R.F., Johne, R., Schlüter, O., Schwarzenbolz, U., et al., 2021. Aspects of high
794 hydrostatic pressure food processing: perspectives on technology and food safety. *Compr. Rev. Food Sci.*
795 *Food Saf.* 20(4), 3225-3266.
- 796 Agostoni, C., Axelsson, I., Goulet, O., Koletzko, B., Michaelsen, K.F., Puntis, J., et al., 2006. Soy protein infant
797 formulae and follow-on formulae: a commentary by the ESPGHAN Committee on Nutrition. *J. Pediatr.*
798 *Gastroenterol. Nutr.* 42(4), 352–361.
- 799 Agostoni, C., Braegger, C., Decsi, T., Kolacek, S., Koletzko, B., Michaelsen, K.F., et al., 2009. Breast-feeding: A
800 commentary by the ESPGHAN Committee on Nutrition. *J. Pediatr. Gastroenterol. Nutr.* 49(1), 112-125.
- 801 Ahmadova, A., Dimov, S., Ivanova, I., Choiset, Y., Chobert, J. M., Kuliev, A., et al., 2011. Proteolytic activities
802 and safety of use of Enterococci strains isolated from traditional Azerbaijani dairy products. *Eur. Food Res.*
803 *Technol.* 233, 131-140.
- 804 Ahmed, I., Lv, L., Lin, H., Li, Z., Ma, J., Guanzhi, C., et al., 2018. Effect of tyrosinase-aided crosslinking on the
805 IgE binding potential and conformational structure of shrimp (*Metapenaeus ensis*) tropomyosin. *Food*
806 *Chem.* 248, 287– 295.
- 807 Ahmed, I., Lin, H., Xu, L., Li, S., Costa, J., Mafra, I., et al., 2020. Immunomodulatory effect of laccase/caffeic
808 acid and transglutaminase in alleviating shrimp tropomyosin (Met e 1) allergenicity. *J. Agric. Food*
809 *Chem.* 68(29), 7765– 7778.
- 810 Ahmed, I., Chen, H., Li, J., Wang, B., Li, Z., Huang, G., 2021. Enzymatic crosslinking and food allergenicity: A
811 comprehensive review. *Compr. Rev. Food Sci. Food Saf.* 20(6), 5856-5879.
- 812 Arasi, S., Cafarotti, A., Fiocchi, A., 2022. Cow's milk allergy. *Curr. Allergy Clin. Immunol.* 22(3):181-187.
- 813 Audic, J-L., Chaufer, B., Daufin, G., 2003. Non-food applications of milk components and dairy coproducts: a
814 review. *Le Lait* 83(6), 417–438.
- 815 Auestad, N., Layman, D.K., 2021. Dairy bioactive proteins and peptides: a narrative review. *Nutr. Rev.* 79
816 (Suppl._2), 36-47
- 817 Azuma, N., Nagaune, S.I., Ishino, Y., Mori, H., Kaminogawa, S., Yamauchi, K., 1989. DNA-synthesis stimulating
818 peptides from human β -casein. *Agric. Biol. Chem.* 53(10), 2631-2634.
- 819 Bavaro, S.L., Di Stasio, L., Mamone, G., De Angelis, E., Nocerino, R., Berni Canani, R. et al., 2018. Effect of
820 thermal/pressure processing and simulated human digestion on the immunoreactivity of extractable
821 peanut allergens. *Food Res. Int.* 109, 126-137.
- 822 Bavaro, S.L, De Angelis, E., Barni, S., Pilolli, R., Mori, F., Novembre, E.M., et al., 2019. Modulation of Milk
823 Allergenicity by Baking Milk in Foods: A Proteomic Investigation. *Nutrients* 11(7), 1536.
- 824 Bhattacharyya, J., Das, K.P., 1999. Molecular chaperone-like properties of an unfolded protein, α s-casein. *J.*
825 *Biol. Chem.* 274(22), 15505-15509
- 826 Boyce, J.A., Assa'ad, A., Burks, A.W., Jones, S.M., Sampson, H.A., Wood, R.A., et al., 2011. Guidelines for the
827 diagnosis and management of food allergy in the United States: Summary of the NIAID-sponsored expert
828 panel report. *J. Allergy Clin. Immunol.* 64(1), 175-192.
- 829 Bridgman, P.W., 1914. Change of phase under pressure. I. The phase diagram of eleven substances with
830 especial reference to the melting curve. *Phys. Rev.* 3(3), 153.
- 831 Brignon, G., Dumas, B.R., Mercier, J.C., Pelissier, J.P., Das, B.C., 1977. Complete amino acid sequence of
832 bovine α S2-casein. *FEBS letters*, 76(2), 274-279.

833 Busse, P.J., Järvinen, K.M., Vila, L., Beyer, K., Sampson, H.A., 2002. Identification of sequential IgE-binding
834 epitopes on bovine α 2-casein in cow's milk allergic patients. *Int Arch Allergy Immunol.* 129(1), 93-96.

835 Cabanillas, B., Novak, N., 2019. Effects of daily food processing on allergenicity. *Crit Rev Food Sci Nutr* 59(1),
836 31-42.

837 Carnés, J., Ferrer, A., Huertas, A.J., Andreu, C., Larramendi, C.H., Fernández-Caldas, E., et al., 2007. The use
838 of raw or boiled crustacean extracts for the diagnosis of seafood allergic individuals. *Ann. Allergy Asthma*
839 *Immunol.* 98(4), 349–54.

840 Caroli, A.M., Chessa, S., Erhardt, G.J., 2009. Invited review: Milk protein polymorphisms in cattle: Effect on
841 animal breeding and human nutrition. *J. Dairy Sci.* 92(11), 335–5352.

842 Cerecedo, I., Zamora, J., Shreffler, W.G., Lin, J., Bardina, L., Dieguez, M.C., et al., 2008. Mapping of the IgE and
843 IgG4 sequential epitopes of milk allergens with a peptide microarray-based immunoassay. *J. Allergy Clin.*
844 *Immunol.* 122(3), 589-594.

845 Chabance, B., Marteau, P., Rambaud, J.C., Migliore-Samour, D., Boynard, M., Perrotin, P., et al., 1998. Casein
846 peptide release and passage to the blood in humans during digestion of milk or yogurt. *Biochimie* 80(2),
847 155-165.

848 Chatchatee, P., Jarvinen, K.M., Bardina, L., Beyer, K., Sampson, H.A., 2001. Identification of IgE- and IgG-
849 binding epitopes on α S1-casein: differences in patients with persistent and transient cow's milk allergy. *J.*
850 *Allergy Clin. Immunol.* 107(2), 379–83.

851 Chobert, J.M., 2012. Milk protein tailoring to improve functional and biological properties.
852 *J. Biosci. Biotechnol.* 1(3), p171-197.

853 Clare, D.A., Swaisgood, H.E., 2000. Bioactive milk peptides: a prospectus. *J. Dairy Sci.* 83(6), 1187-1195.

854 Cong, Y., Yi, H., Qing, Y., Li, L., 2012. Identification of the critical amino acid residues of immunoglobulin E and
855 immunoglobulin G epitopes on α S1-casein by alanine scanning analysis. *J. Dairy Sci.* 95:6307–12.

856 Creamer, L.K., Richardson, T., Parry, D.A.D., 1981. Secondary structure of bovine α s1-and β -casein in
857 solution. *Arch. Biochem. Biophys.* 211(2), 689-696.

858 Creamer, L.K., Plowman, J.E., Liddell, M.J., Smith, M.H., Hill, J.P., 1998. Micelle stability: κ -casein structure
859 and function. *J. Dairy Sci.* 81(11), 3004-3012.

860 Cuadrado, C., Sanchiz, A., Vicente, F., Ballesteros, I., Linacero, R., 2020. Changes induced by pressure
861 processing on immunoreactive proteins of tree nuts. *Molecules* 25(4), 954.

862 Cuomo, B., Indirli, G.C., Bianchi, A., Arasi, S., Caimmi, D., Dondi, A., et al., 2017. Specific IgE and skin prick
863 tests to diagnose allergy to fresh and baked cow's milk according to age: A systematic review. *Ital. J.*
864 *Pediatr.* 43, 1–10.

865 Dang, T.D., Peters, R.L., Allen, K.J., 2016. Debates in allergy medicine: baked egg and milk do not accelerate
866 tolerance to egg and milk. *World Allergy Organ. J.* 9,2.

867 Dantzer, J., Dunlop, J., Psoter, K.J., Keet, C., Wood, R., 2022. Efficacy and safety of baked milk oral
868 immunotherapy in children with severe milk allergy: A randomized, double-blind, placebo-controlled
869 phase 2 trial. *J. Allergy Clin. Immunol.* 149(4),1383-1391.

870 Davis, P., Williams, S., 1998. Protein modification by thermal processing. *Allergy* 53, 102–105.

871 De Angelis, E., Bavaro, S.L., Forte, G., Pilolli, R., Monaci, L., 2018. Heat and pressure treatments on almond
872 protein stability and change in immunoreactivity after simulated human digestion. *Nutrients* 10(11),
873 1679.

874 De Angelis, E., Di Bona, D., Pilolli, R., Liodice, R., Luparelli, A., Gilberti, L. et al., 2022. In vivo and in vitro
875 assessment and proteomic analysis of the effectiveness of physical treatments in reducing allergenicity of
876 hazelnut proteins. *Nutrients* 14(4), 874.

877 De Kruif, C.G., Holt, C., 2003. Casein micelle structure, functions and interactions. In *Advanced dairy*
878 *chemistry—1 proteins: part a/part b.* Boston, MA: Springer US, pp. 233-276.

879 De la Hoz, L., Netto, F.M., 2008. Structural modifications of β -lactoglobulin subjected to gamma radiation.
880 Int. Dairy J. 18(12), 1126–1132.

881 de Silva, D., Rodriguez Del Rio, P., de Jong N.W., Khaleva, E., Singh, C., Nowak-Wegrzyn, A., et al., 2022
882 Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: a systematic review and meta-
883 analysis. Allergy 77(6), 1852-1862.

884 Delfour, A., Jolles, J., Alais, C., Jolles, P., 1965. Caseino-glycopeptides: Characterization of a methionine
885 residue and of the N-terminal sequence. Biochem. Biophys. Res. Commun. 19(4), 452-455.

886 Doherty, T.M., Asotra, K., Fitzpatrick, L.A., Qiao, J. H., Wilkin, D.J., Detrano, R.C., et al., 2003. Calcification in
887 atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc. Natl. Acad.
888 Sci. 100(20), 11201-11206

889 Dong, X., Wang, J., Raghavan, V., 2021. Critical reviews and recent advances of novel non-thermal processing
890 techniques on the modification of food allergens. Crit. Rev. Food Sci. Nutr. 61(2), 196-210.

891 EFSA, 2009. European Food Safety Authority Report: dairy protein is beneficial to human health Retrieved
892 25.03.09, from [http://www.euromilk.org/upload/docs/EDA/PR%20EFSA%20Report%20beta-](http://www.euromilk.org/upload/docs/EDA/PR%20EFSA%20Report%20beta-casein.pdf)
893 [casein.pdf](http://www.euromilk.org/upload/docs/EDA/PR%20EFSA%20Report%20beta-casein.pdf)EFSA (2009)

894 Eigenmann, P.A., Ebisawa, M., Greenhawt, M., O'B Hourihane, J., Perry, T.T., Remington, B.C., et al., 2021.
895 Addressing risk management difficulties in children with food allergies. Pediatr. Allergy Immunol. 32(4),
896 658–666.

897 Ekezie, F.G.C., Cheng, J-H., Sun, D-W., 2018. Effects of non-thermal food processing technologies on food
898 allergens: a review of recent research advances. Trends Food Sci. Technol. 74, 12-25.

899 Farrell, Jr, H.M., Jimenez-Flores, R., Bleck, G.T., Brown, E.M., Butler, J.E., Creamer, L.K., et al., 2004.
900 Nomenclature of the proteins of cows' milk—Sixth revision. J. Dairy Sci. 87(6), 1641-1674.

901 Fei, D.X., Liu, Q.M., Chen, F., Yang, Y., Chen, Z.W., Cao, M.J., et al., 2016. Assessment of the sensitizing
902 capacity and allergenicity of enzymatic cross-linked arginine kinase, the crab allergen. Mol. Nutr. Food
903 Res. 60(7), 1707–1718.

904 Fierro, V., Valluzzi, R.L., Banzato, C., Plaza, M.A., Bosque, M., Íbero, M., et al., 2020. A well tolerated new
905 amino acid-based formula for cow's milk allergy. Immun. Inflamm. Dis. 8(2), 140–149.

906 Flom, J.D.; Sicherer, S.H., 2019. Epidemiology of cow's milk allergy. Nutrients 11(5), 1051.

907 Foegeding, E.A., Davis, J.P., 2011. Food protein functionality: A comprehensive approach. Food
908 Hydrocoll. 25(8), 1853-1864.

909 Foegeding, E.A., 2015. Food protein functionality—A new model. J. Food Sci. 80(12), C2670-C2677.

910 Fox, P., 2001. Milk proteins as food ingredients. Int. J. Dairy Technol. 54(2), 41–55.

911 Fox, P.F., Uniacke-Lowe, T., McSweeney, P.L.H., O'Mahony, J.A., Fox, P.F., Uniacke-Lowe, T., et al., 2015. Heat-
912 induced changes in milk. Dairy chem. Biochem. 345-375.

913 Gambacorta, N., Caputo, L., Quintieri, L., Monaci, L., Ciriaco, F., Nicolotti, O., 2022. Rational Discovery of
914 Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main
915 Protease. Biomedicines, 10(5), 1067.

916 Gandhi, A., Shah, N.P., 2014. Cell growth and proteolytic activity of Lactobacillus acidophilus, Lactobacillus
917 helveticus, Lactobacillus delbrueckii ssp. bulgaricus, and Streptococcus thermophilus in milk as affected
918 by supplementation with peptide fractions. Int. J. Food Sci. Nutr. 65(8), 937-941.

919 Geiselhart, S., Podzhilkova, A., Hoffmann-Sommergruber, K., 2021. Cow's Milk Processing-Friend or Foe in
920 Food Allergy?. Foods 10(3), 572.

921 Giannetti, A., Toschi Vespasiani, G., Ricci, G., Miniaci, A., di Palma, E., Pession, A., 2015. Cow's Milk Protein
922 Allergy as a Model of Food Allergies. Nutrients 13(5), 1525.

923 Giglioti, R., Gutmanis, G., Katiki, L.M., Okino, C.H., Cristinade, M., Oliveira, S., et al., 2020. New high-sensitive
924 rhAmp method for A1 allele detection in A2 milk samples. Food Chem. 313, 126167.

925 Goldberg, M.R., Nachshon, L., Appel, M.Y., Elizur, A., Levy, M.B., Eisenberg, E., et al., 2015. Efficacy of baked
926 milk oral immunotherapy in baked milk-reactive allergic patients. *J. Allergy Clin. Immunol.* 136(6), 1601–
927 1606.

928 Han, N., Järvinen, K., Cocco, R., Busse, P., Sampson, H., Beyer, K., 2008. Identification of amino acids critical
929 for IgE-binding to sequential epitopes of bovine κ -casein and the similarity of these epitopes to the
930 corresponding human κ -casein sequence. *Allergy* 63(2), 198–204.

931 Han, Z., Cai, M.J., Cheng, J.H., Sun, D.W., 2018. Effects of electric fields and electromagnetic wave on food
932 protein structure and functionality: a review. *Trends Food Sci. Technol.* 75, 1–9.

933 Heyman, M., Grasset, E., Duroc, R., Desjeux, J.F., 1988. Antigen absorption by the jejunal epithelium of
934 children with cow's milk allergy. *Pediatr. Res.* 24(2), 197–202.

935 Holt, C., Sawyer, L., 1993. Caseins as rheomorphic proteins: Interpretation of primary and secondary
936 structures of the α S1-, β - and κ -caseins *Journal of the Chemical Society, Faraday Transactions*, 89 (15),
937 pp. 2683-2692

938 Holt, C., Timmins, P.A., Errington, N., Leaver, J., 1998. A core-shell model of calcium phosphate nanoclusters
939 stabilized by beta-casein phosphopeptides, derived from sedimentation equilibrium and small-angle X-
940 ray and neutron-scattering measurements. *Eur. J. Biochem.* 252(1) 73-78.

941 Holt, C., Carver, J.A., Ecroyd, H., Thorn, D.C., 2013. Invited review: caseins and the casein micelle: their
942 biological functions, structures, and behavior in foods. *J. Dairy Sci.* 96(10), 6127–6146.

943 Huang, H.W., Yang, B.B., Wang, C. Y., 2014. Effects of high pressure processing on immunoreactivity and
944 microbiological safety of crushed peanuts. *Food Control* 42, 290–295.

945 Huppertz, T., 2013. Chemistry of the Caseins. In *Advanced Dairy Chemistry: Volume 1A: Proteins: Basic*
946 *Aspects*, 4th Edition (pp. 135-160). Boston, MA: Springer US

947 Huppertz, T., Fox, P.F., Kelly, A.L., 2018. The caseins: Structure, stability, and functionality. In *Proteins in food*
948 *processing*, pp. 49-92. Woodhead Publishing.

949 Jaiswal, L., Worku, M., 2022. Recent perspective on cow's milk allergy and dairy nutrition. *Crit. Rev. Food Sci.*
950 *Nutr.*, 62(27), 7503-7517.

951 Järvinen, K.M., Beyer, K., Vila, L., Chatchatee, P., Busse, P.J., Sampson, H.A., 2002. B-cell epitopes as a
952 screening instrument for persistent cow's milk allergy. *J. Allergy Clin. Immunol.* 110(2), 293-297.

953 Kaminski, S., Cieslinska, A., Kostyra, E., 2007. Polymorphism of bovine beta-casein and its potential effect on
954 human health. *J. Appl. Genet.* 48, 189–198.

955 Kaneko, H., Teramoto, T., Kondo, M., Morita, H., Ohnishi, H., Orii, K., et al. 2010. Efficacy of the slow dose-up
956 method for specific oral tolerance induction in children with cow's milk allergy: comparison with reported
957 protocols. *J. Investig. Allergol. Clin. Immunol.* 20(6), 538–539; 67.

958 Karimidastjerd, A., Gulsunoglu-Konuskan, Z., 2021. Biological, functional and nutritional properties of
959 caseinomacropeptide from sweet whey. *Crit. Rev. Food Sci. Nutr.* 1-13.

960 Kasera, R., Singh, A. B., Kumar, R., Lavas, S., Prasad, K.N., Arora, N., 2012. Effect of thermal processing and γ -
961 irradiation on allergenicity of legume proteins. *Food Chem. Toxicol.* 50(10), 3456-3461.

962 Kawahara, T., Tesuka, J., Ninomiya, T., Honjo, S., Masumoto, N., Nanishi, M., et al., 2019. Risk prediction of
963 severe reaction to oral challenge test of cow's milk. *Eur. J. Pediatr.* 178:181–188.

964 Kim, J.S., Nowak-Węgrzyn, A., Sicherer, S.H., Noone, S., Moshier, E.L., Sampson, H.A., 2011. Dietary baked
965 milk accelerates the resolution of cow's milk allergy in children. *J. Allergy Clin. Immunol.* 128(1), 125–131.

966 Kipfer, S., Goldman, R.D., 2021. Formula choices in infants with cow's milk allergy. *Canadian Family*
967 *Physician* 67(3), 180-182

968 Kitts, D.D., Weiler, K., 2003. Bioactive proteins and peptides from food sources. Applications of bioprocesses
969 used in isolation and recovery. *Current pharmaceutical design*, 9(16), 1309-1323.

970 Komata, T., Söderström, L., Borres, M.P., Tachimoto, H., Ebisawa, M., 2007. The predictive relationship of
971 food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age. *J.*
972 *Allergy Clin. Immunol.* 119(5), 1272-1274.

973 Korhonen, H., Pihlanto-Leppälä, A., Rantamäki, P., Tupasela, T., 1998. The functional and biological properties
974 of whey proteins: prospects for the development of functional foods. *Agric. Food Sci.* 7(2), 283-296.

975 Lam, H.Y., Van Hoffen, E., Michelsen, A., Guikers, K., Van Der Tas, C.H.W., Bruijnzeel-Koomen, C.A.F.M., et al.,
976 2008. Cow's milk allergy in adults is rare but severe: both casein and whey proteins are involved. *Clin. Exp.*
977 *Allergy* 38(6), 995-1002.

978 Latham, P.W., 1999. Therapeutic peptides revisited. *Nature biotechnology* 17(8), 755-757.

979 Le Vay, K., Carter, B.M., Watkins, D.W., Dora Tang, T-Y., Ting, V.P., Cölfen, H., et al 2020. Controlling protein
980 nanocage assembly with hydrostatic pressure. *J. Am. Chem. Soc.* 142(49), 20640-20650.

981 Lee, J.W., Kim, J.H., Yook, H.S., Kang K.S., Lee S.Y.Y, Hwang, H.J., et al., 2001. Effects of gamma radiation on
982 the allergenic and antigenic properties of milk proteins. *J. Food Prot.* 64(2), 272–276.

983 Leonard, S. A., Nowak-Węgrzyn, A. H. 2016. Baked milk and egg diets for milk and egg allergy management.
984 *Immunol. Allergy Clin. N. Am.* 36(1), 147-159.

985 Li, X., Li, S., Liang, X., McClements, D.J., Liu, X., Liu, F., 2020. Applications of oxidases in modification of food
986 molecules and colloidal systems: Laccase, peroxidase and tyrosinase. *Trends Food Sci. Technol.* 103, 78-
987 93.

988 Lisson, M., Novak, N., Erhardt, G., 2014. Immunoglobulin E epitope mapping by microarray immunoassay
989 reveals differences in immune response to genetic variants of caseins from different ruminant species. *J.*
990 *Dairy Sci.* 97(4), 1939-1954.

991 Liu, D., Lv, X., Cong, Y., Li, L.A., 2022. Method for Screening Proteases That Can Specifically Hydrolyze the
992 Epitope AA83-105 of α s1-Casein Allergen. *Foods* 11(21), 3322.

993 Loi, M., Quintieri, L., Fanelli, F., Caputo, L., Mulè, G., 2018. Application of a recombinant laccase-chlorogenic
994 acid system in protein crosslink and antioxidant properties of the curd. *Food Res. Int.* 106, 763-770.

995 Loi, M., Quintieri, L., De Angelis, E., Monaci, L., Logrieco, A.F., Caputo, L., et al., 2020. Yield improvement of
996 the Italian fresh Giuncata cheese by laccase-induced protein crosslink. *Int. Dairy J.* 100, 104555.

997 López-Expósito, I., Gómez-Ruiz, J.Á., Amigo, L., Recio, I., 2006. Identification of antibacterial peptides from
998 ovine α s2-casein. *Int. Dairy J.* 16(9), 1072-1080.

999 Mattinen, M.L., Kruus, K., Buchert, J., Nielsen, J.H., Andersen, H.J., Steffensen, C.L., 2005. Laccase-catalyzed
1000 polymerization of tyrosine-containing peptides. *FEBS Journal* 272(14), 3640-3650.

1001 Meersman, F., McMillan, P.F., 2014. High hydrostatic pressure: a probing tool and a necessary parameter in
1002 biophysical chemistry. *Chem. Comm.* 50(7), 766-775.

1003 Meng, F., Uniacke-Lowe, T., Ryan, A.C., & Kelly, A.L. (2021). The composition and physico-chemical properties
1004 of human milk: A review. *Trends Food Sci. Technol.* 112, 608-621.

1005 Meyer, R., 2018. Nutritional disorders resulting from food allergy in children. *Pediatr. Allergy Immunol.* 29(7),
1006 689–704.

1007 Migliore-Samour, D., Jolles, P., 1988. Casein, a prohormone with an immunomodulating role for the
1008 newborn?. *Experientia* 44, 188-193.

1009 Mills, E.N., Sancho, A.I., Rigby, N.M., Jenkins, J.A., Mackie, A.R., 2009. Impact of food processing on the
1010 structural and allergenic properties of food allergens. *Mol Nutr Food Res.* 53(8), 963–969.

1011 Monaci, L., Lamonaca, A., Luparelli, A., Pilolli, R., De Angelis, E., 2023. (Bio)technological Approaches for
1012 Reducing Allergenicity of Food Ingredients. In: Ferranti, P. (Ed.), *Sustainable Food Science: A*
1013 *Comprehensive Approach*, vol. 1. Elsevier, pp. 86–102.

1014 Monti, G., Viola, S., Baro, C., Cresi, F., Tovo, P.A., Moro, G., et al., 2012. Tolerability of donkey's milk in 92
1015 highlyproblematic cow's milk allergic children. *J. Biol. Regul. Homeost. Agents* 26(3), 75–82.

1016 Mousan, G., Kamat, D., 2016. Cow's milk protein allergy. *Clin. Pediatr.* 55 (11), 1054–1063.

1017 Nadeau, K.C., Schneider, L.C., Hoyte, L., Borrás, I., Umetsu, D.T., 2011. Rapid oral desensitization in
1018 combination with omalizumab therapy in patients with cow's milk allergy. *J. Allergy Clin. Immunol.* 127(6),
1019 1622–1624.

1020 Nakajima-Adachi, H., Hachimura, S., Ise, W., Honma, K., Nishiwaki, S., Hirota, M., et al., 1998. Determinant
1021 analysis of IgE and IgG4 antibodies and T cells specific for bovine α S1-casein from the same patients
1022 allergic to cow's milk: existence of α S1-casein-specific B cells and T cells characteristic in cow's milk allergy.
1023 *J. Allergy Clin. Immunol.* 101(5), 660–71.

1024 Natale, M., Bisson, C., Monti, G., Peltran, A., Perono Garoffo L., Valentini S., et al., 2004. Cow's milk allergens
1025 identification by two-dimensional immunoblotting and mass spectrometry. *Mol. Nutr. Food Res.* 48(5),
1026 363–369.

1027 Navarrete-Rodríguez, E.M., Rlos-Villalobos, L.A., Alcocer-Arreguln, C.R., Del-Rio-Navarro, B.E., Del Rio-
1028 Chivardi, J.M., Saucedo-Ramírez, O.J., 2018. Cross-over clinical trial for evaluating the safety of camel's
1029 milk intake in patients who are allergic to cow's milk protein. *Allergol. Immunopathol.* 46(2), 149–154.

1030 Ng, S. W., Lu, P., Rulikowska, A., Boehm, D., O'Neill, G., Bourke, P., 2021. The effect of atmospheric cold
1031 plasma treatment on the antigenic properties of bovine milk casein and whey proteins. *Food Chem.* 342,
1032 128283.

1033 Nowak-Węgrzyn, A., Bloom, K.A., Sicherer, S.H., Shreffler, W.G., Noone, S., Wanich, N., et al., 2008. Tolerance
1034 to extensively heated milk in children with cow's milk allergy. *J. Allergy Clin. Immunol.* 122(2), 342–347.

1035 Nowak-Węgrzyn, A., Assa'ad, A.H., Bahna, S.L., Bock, S.A., Sicherer, S.H., Teuber, S.S., 2009. Work group
1036 report: Oral food challenge testing. Adverse reactions to food committee of American academy of allergy,
1037 asthma & immunology. *J. Allergy Clin. Immunol.* 123 (Suppl. 6), S365–S383.

1038 Nurmatov, U., Dhimi, S., Arasi, S., Pajno, G.B., Fernandez-Rivas, M., Muraro, A., et al., 2017.
1039 Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. *Allergy*
1040 72(8), 1133–1147.

1041 Nwaru, B.I., Hickstein, L., Panesar, S.S., Roberts, G., Muraro, A., Sheikh, A., 2014. Prevalence of common food
1042 allergies in Europe: A systematic review and meta-analysis. *Allergy Eur. J. Allergy Clin. Immunol.* 69(8),
1043 992–1007.

1044 O'Donoghue, L.T., & Murphy, E.G., 2023. Nondairy food applications of whey and milk permeates: Direct and
1045 indirect uses. *Compr. Rev. Food Sci. Food Saf.* 22(4), p.2652-2677.

1046 Pajno, G.B., Caminiti, L., Salzano, G., Crisafulli, G., Aversa, T., Messina, M.F., et al., 2013. Comparison between
1047 two maintenance feeding regimens after successful cow's milk oral desensitization. *Pediatr. Allergy*
1048 *Immunol.* 24(4), 376–381.

1049 Pajno, G.B., Fernandez-Rivas, M., Arasi, S., Roberts, G., Akdis, C.A., Alvaro-Lozano, M., et al., 2018. EAACI
1050 Allergen Immunotherapy Guidelines Group. EAACI Guidelines on allergen immunotherapy: IgE-mediated
1051 food allergy. *Allergy* 73(4), 799–815.

1052 Pan, D., Tang, B., Liu, H., Li, Z., Ma, F., Peng, Y., et al., 2020. Effect of high hydrostatic pressure (HHP)
1053 processing on immunoreactivity and spatial structure of peanut major allergen Ara h 1. *Food Bioprocess*
1054 *Technol.* 13(1), 132–144.

1055 Pastorello, E.A., Pravettoni, V., Farioli, L., Primavesi, L., Scibilia, J., Piantanida, M., et al., 2010. Green bean
1056 (*Phaseolus vulgaris*): a new source of IgE-binding lipid transfer protein. *J. Agric. Food Chem.* 58(7), 4513–
1057 16.

1058 Petrat-Melin, B., Andersen, P., Rasmussen, J.T., Poulsen, N.A., Larsen, L.B., Young, J.F., 2015. In vitro digestion
1059 of purified-casein variants A 1, A 2, B, and I: Effects on antioxidant and angiotensin-converting enzyme
1060 inhibitory capacity. *J. Dairy Sci.* 98(1), 15–26.

1061 Pettersson, M.E., Koppelman, G.H., Flokstra-de Blok, B.M.J., Kollen, B.J., Dubois, A.E.J., 2018. Prediction
1062 of theseverityofallergic reactionstofoods. *Allergy* 73(7), 1532–1540.

1063 Pi, X., Yang, Y., Sun, Y., Wang, X., Wan, Y.Y, Fu, G., et al., 2021. Food irradiation: a promising technology to
1064 produce hypoallergenic food with high quality. *Crit. Rev. Food Sci. Nutr.* 62(24), 6698-6713.

1065 Poulsen, O.M., Hau, J., Kollerup, J., 1987. Effect of homogenization and pasteurization on the allergenicity of
1066 bovine milk analysed by a murine anaphylactic shock model. *Clin. Exp. Allergy.* 17(5), 449-458.

1067 Quintieri, L., Monaci, L., Baruzzi, F., Giuffrida, M. G., de Candia, S., Caputo, L., 2017. Reduction of whey protein
1068 concentrate antigenicity by using a combined enzymatic digestion and ultrafiltration approach. *J. Food
1069 Sci. Technol.* 54, 1910-1916.

1070 Ranadheera, C.S., Liyanaarachchi, W.S., Chandrapala, J., Dissanayake, M., Vasiljevic, T., 2016. Utilizing unique
1071 properties of caseins and the casein micelle for delivery of sensitive food ingredients and
1072 bioactives. *Trends Food Sci. Technol.* 57, 178-187.

1073 Rival, S.G., Fornaroli, S., Boeriu, C.G., Wichers, H.J., 2001. Caseins and casein hydrolysates. 1. Lipoxygenase
1074 inhibitory properties. *J. Agric. Food Chem.* 49(1), 287-294.

1075 Roche, J., Royer, C.A., 2018. Lessons from pressure denaturation of proteins. *J. R. Soc. Interface.* 15(147),
1076 20180244.

1077 Rona, R.J., Keil, T., Summers, C., Gislason, D., Zuidmeer, L., Sodergren, E., et al., 2007. The prevalence of food
1078 allergy: A meta-analysis. *J. Allergy Clin. Immunol.* 120(3), 638–646.

1079 Rubio, A., Vivinus-Nébot, M., Bourrier, T., Saggio, B., Albertini, M., Bernard, A., 2011. Benefit of the basophil
1080 activation test in deciding when to reintroduce cow’s milk in allergic children. *Allergy* 66(1), 92–100.

1081 Ruiten, B., Tregoeat, V., M'Rabet, L., Garssen, J., Bruijnzeel-Koomen, C.A.F.M., Knol, E.F., et al., 2006.
1082 Characterization of T cell epitopes in α 1-casein in cow's milk allergic, atopic and non-atopic children. *Clin
1083 Exp Allergy* 36(3), 303-310.

1084 Sadiq, U., Gill, H., Chandrapala, J., 2021. Casein micelles as an emerging delivery system for bioactive food
1085 components. *Foods*, 10(8), 1965.

1086 Sampson, H.A., Aceves, S., Bock, S.A., James, J., Jones, S., Lang, D., et al. 2014. Food allergy: A practice
1087 parameter update-2014. *J. Allergy Clin. Immunol.* 134(5), 1016–1025.

1088 Santos, A.F., Douiri, A., Becares, N., Wu, S-Y., Stephens, A., Radulovic, S., et al., 2014. Basophil activation test
1089 discriminates between allergy and tolerance in peanut-sensitized children. *J Allergy Clin. Immunol.* 134(3),
1090 645–652.

1091 Santos, A.F., Du Toit, G., O'Rourke, C., Becares, N., Couto-Francisco, N., Radulovic, S., et al., 2020. Biomarkers
1092 of severity and threshold of allergic reactions during oral peanut challenges. *J. Allergy Clin. Immunol.*
1093 146(2), 344–355.

1094 Sarkar, R.K., Ghosh, N., Sircar, G., Saha, S., 2023. Updates on Databases of Allergens and Allergen-Epitopes.
1095 In *Computational Vaccine Design*. New York, NY: Springer US. pp. 151-165.

1096 Savage, J., Johns, C.B., 2015. Food allergy epidemiology and natural history food allergy epidemiology natural
1097 history peanut milk egg. *Immunol. Allergy Clin.* 35(1), 45–59.

1098 Schaar, J., Hansson, B., Pettersson, H.E., 1985. Effects of genetic variants of κ -casein and β -lactoglobulin on
1099 cheesemaking. *J. Dairy Res.* 52(3), 429-437.

1100 Schlüter, O., Ehlbeck, J., Hertel, C., Habermeyer, M., Roth, A., Engel, K-H., et al., 2013. Opinion on the use of
1101 plasma processes for treatment of foods. *Mol Nutr Food Res.* 57(5), 920-927.

1102 Schoemaker, A.A., Sprickelman, A.B., Grimshaw, K.E., Roberts, G., Grabenhenrich, L., Rosenfeld, L., et al.,
1103 2015. Incidence and natural history of challenge-proven cow's milk allergy in European children–
1104 EuroPrevall birth cohort. *Allergy*, 70(8), 963-972.

1105 Selinheimo, E., Lampila, P., Mattinen, M.L., Buchert, J., 2008. Formation of protein–oligosaccharide
1106 conjugates by laccase and tyrosinase. *J. Agric. Food Chem.* 56(9), 3118-3128.

1107 Shriver, S.K., Yang, W.W., 2011. Thermal and non-thermal methods for food allergen control. *Food Eng. Rev.*
1108 3, 26-43.

1109 Silva, S.V., Malcata, F.X., 2005. Caseins as source of bioactive peptides. *Int. Dairy J.* 15(1), 1-15.

1110 Spuerger, P., Mueller, H., Walter, M., Schiltz, E., Forster, J., 1996. Allergenic epitopes of bovine α 1-casein
1111 recognized by human IgE and IgG. *Allergy* 51(5), 306-312.

1112 Stanic, D., Monogioudi, E., Ercili, D., Radosavljevic, J., Atanaskovic-Markovic, M., Vuckovic, O., et al., 2010.
1113 Digestibility and allergenicity assessment of enzymatically crosslinked β -casein. *Mol Nutr Food Res.* 54(9),
1114 1273-1284.

1115 Stanic-Vucinic, D., Stojadinovic, M., Atanaskovic-Markovic, M., Ognjenovic, J., Grönlund, H., van Hage, M., et
1116 al., 2012. Structural changes and allergenic properties of β -lactoglobulin upon exposure to high-intensity
1117 ultrasound. *Mol Nutr Food Res.* 56(12), 1894-1905.

1118 Strozyk, A., Horvath, A., Meyer, R., Szajewska, H., 2020. Efficacy and safety of hydrolyzed formulas for cow's
1119 milk allergy management: a systematic review of randomized controlled trials. *Clin. Exp. Allergy* 50(7),
1120 766–779.

1121 Sun, J., Cai, J., Wang, X., 2014. Real-time ultrasound elastography for differentiation of benign and malignant
1122 thyroid nodules: a meta-analysis. *J. Med. Ultrasound* 33(3), 495-502.

1123 Sun, Z. Cade, J.R. Fregly, M.J. Privette, R.M., 1999. Beta casomorphin induces Fos-like immune reactivity in
1124 discrete brain regions relevant to schizophrenia and autism. *Autism* 3(1), 67–83.

1125 Tammineedi, C.V., Choudhary, R., Perez-Alvarado, G.C., Watson, D.G., 2013. Determining the effect of UV-C,
1126 high intensity ultrasound and non-thermal atmospheric plasma treatments on reducing the allergenicity
1127 of α -casein and whey proteins. *LWT-Food Sci. Technol.* 54(1), 35-41.

1128 Teixeira, P., Kolomeytseva, M., Silva, J., Saraiva, S.M.C.J.A., 2014. High hydrostatic pressure applied to ready-
1129 to-eat meat products. *Front. Food. Sci. Technol.* 1, 14-23.

1130 Thirumdas, R., Sarangapani, C., Annapure, U.S., 2015. Cold plasma: a novel non-thermal technology for food
1131 processing. *Food Biophysics* 10, 1–11.

1132 Thiruvengadam, M., Venkidasamy, B., Thirupathi, P., Chung, I.M., Subramanian, U., 2021. β -Casomorphin: A
1133 complete health perspective. *Food Chem.* 337, 127765.

1134 Tondo, A.R., Caputo, L., Mangiatordi, G. F., Monaci, L., Lentini, G., Logrieco, A.F., et al., 2019. Structure-based
1135 identification and design of angiotensin converting enzyme-inhibitory peptides from whey proteins. *J.*
1136 *Agric. Food Chem.*, 68(2), 541-548.

1137 Trogen, B., Jacobs, S., Nowak-Wegrzyn, A., 2022. Early Introduction of Allergenic Foods and the Prevention
1138 of Food Allergy. *Nutrients* 14(13), 2565.

1139 Van der Ventel, M.L., Nieuwenhuizen, N.E., Kirstein, F., Hikuam, C., Jeebhay, M.F., Swoboda, I., et al., 2011.
1140 Differential responses to natural and recombinant allergens in a murine model of fish allergy. *Mol.*
1141 *Immunol.* 48(4), 637–46.

1142 Vandenplas, Y., De Greef, E., Hauser, B., Paradise Study Group, 2014. Safety and tolerance of a new
1143 extensively hydrolyzed rice protein-based formula in the management of infants with cow's milk protein
1144 allergy. *Eur. J. Pediatr.* 173, 1209-1216.

1145 Vanga, S.K., Singh, A., Raghavan, V., 2017. Review of conventional and novel food processing methods on
1146 food allergens. *Crit. Rev. Food Sci. Nutr.* 57(10), 2077-2094.

1147 Vieira, M.C., Morais, M.B., Spolidoro, J.V., Toporovski, M. S., Cardoso, A.L., Araujo, G.T., et al., 2010. A survey
1148 on clinical presentation and nutritional status of infants with suspected cow/milk allergy. *BMC*
1149 *pediatrics*, 10, 1-7.

1150 Villa, C., Costa, J., Oliveira, M.B.P.P., Mafra, I., 2018. Bovine Milk Allergens: A Comprehensive Review. *Compr.*
1151 *Rev. Food Sci. Food Saf.* 17(1), 137–164.

1152 Wal, J.M., 2003. Thermal processing and allergenicity of foods. *Allergy* 58(8), 727–729.

1153 Walstra, P., Jenness, R., 1984. Dairy chemistry & physics. John Wiley & Sons.
1154 Wan, K., Uraji, M., Tokai, S., Hatanaka, T., 2019. Enzymatic Degradation of Allergen Peptides from Bovine
1155 Casein by a Combination of Streptomyces Aminopeptidases. *Appl. Biochem. Biotechnol.* 187(2), 570–582.
1156 Wang, C., Wang, Y., Liu, G., Fu, L., 2020a. Food allergomics based on high-throughput and bioinformatics
1157 technologies. *Int. Food Res.* 130, 108942
1158 Wang, C., Xie, Q., Wang, Y., Fu, L., 2020b. Effect of ultrasound treatment on allergenicity reduction of milk
1159 casein via colloid formation. *J. Agric. Food Chem.* 68(16), 4678-4686.
1160 Wood, R.A., 2017. Oral immunotherapy for food allergy. *J. Investig. Allergol. Clin. Immunol.* 27(3), 151–159.
1161 Woodford, K.B., 2021. Casomorphins and gliadorphins have diverse systemic effects spanning gut, brain and
1162 internal organs. *Int. J. Environ. Res. Public Health* 18(15), 7911.
1163 Yang, F., Ma, X., Hu, W., Xiong, Z., Huang, M., Wu, Y., et al., 2022. Identification of immunoglobulin E epitopes
1164 on major allergens from dairy products after digestion and transportation in vitro. *J. Dairy Sci.* 105(12),
1165 9476-9487.
1166 Yao, M., Luo, Y., Shi, J., Zhou, Y., Xu, Q., Li, Z., 2014. Effects of fermentation by *Lactobacillus rhamnosus* GG
1167 on the antigenicity and allergenicity of four cows' milk proteins. *Food Agric. Immunol.*, 25(4), 545-555.
1168 Zeng, J., Zou, J., Zhao, J., Lin, K., Zhang, L., Yi, H., Gong, P., 2023. Chymosin pretreatment accelerated papain
1169 catalysed hydrolysis for decreasing casein antigenicity by exposing the cleavage site at tyrosine
1170 residues. *Food Chem.* 404, 134777
1171 Zhang, C., Freddolino, P.L., Zhang Y., 2017. Cofactor: Improved protein function prediction by combining
1172 structure, sequence and protein-protein interaction information. *Nucleic Acids Res.* 45(W1), W291–
1173 W299.
1174 Zhao, S., Pan, F., Cai, S., Yi, J., Zhou, L., Liu, Z., 2023. Secrets behind Protein Sequences: Unveiling the Potential
1175 Reasons for Varying Allergenicity Caused by Caseins from Cows, Goats, Camels, and Mares Based on
1176 Bioinformatics Analyses. *Int. J. Mol. Sci.* 24(3),2481.
1177 Zhu, Q., Tang, X., Lu, M., Chen, J., 2022. Structure and immunoreactivity of purified Siberian apricot (*Prunus*
1178 *sibirica* L.) kernel allergen under high hydrostatic pressure treatment. *Food Biosci.* 48, 101727.
1179
1180
1181
1182